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Introductory chapter: Thesis overview 
Epilepsy is a chronic neurological condition characterised by seizures from 
excessive or synchronous neuronal activity in the brain (Fisher et al., 2014) which 
affects approximately 50 million people worldwide (World Health Organisation; 
WHO, 2017). People with epilepsy (PWE) tend to have worse quality of life (QOL) 
than the general population (Kwon & Park, 2014). Co-morbid psychological 
difficulties, such as anxiety and depression are major detriments of this, above that of 
seizure frequency and severity (Johnson, Jones, Seidenberg & Hermann, 2004) and 
the adverse effects associated with anti-epileptic drugs (AED’s) (Kwon & Park, 
2011). The prevalence of anxiety and depression in PWE is significantly higher than 
in the general population, with up to 30% of PWE meeting diagnostic criteria for 
anxiety or depression (Rai et al., 2012) and several experiencing subclinical forms 
(Kanner, 2009). The negative effects of anxiety and depression for PWE means it is 
imperative that once identified, effective interventions should be implemented (Barry 
et al., 2008). Through offering two specific chapters, this thesis aimed to explore 
psychological interventions for anxiety and depression in PWE. 
Chapter one details a systematic review of randomised controlled trials (RCT’s) that 
had a primary aim to reduce symptoms of anxiety or depression in PWE using a 
psychological intervention. Through applying clinical significance criteria from 
Jacobsen and colleagues (Jacobson, Follette & Revenstorf, 1984; Jacobson & Truax, 
1991) to individual patient data from these RCTs, it was sought to establish both the 
relative and absolute efficacy of psychological interventions for anxiety and 
depression in PWE to help inform clinical practice. To set the path for the review, the 
introduction offers evidence on the prevalence and detrimental effects of anxiety and 
depression in PWE, why psychological interventions are of particular importance for 
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PWE, and how previous systematic reviews have left several critical questions 
concerning the effectiveness of treatments unanswered. 
Following this a methods section states how studies were selected for the review and 
how the data was analysed from the studies. The chapter then goes on to synthesise 
the results of the review. These showed that all studies contained methodological 
limitations and when their individual patient data was subjected to Jacobsen criteria 
(Jacobson, Follette & Revenstorf, 1984; Jacobson & Truax, 1991), the rate of 
participants classed as ‘treatment responders’ was low and the vast majority of 
participants made ‘no reliable change’ after psychological intervention. The review 
did not fully meet its initial aim as no calculation of the absolute efficacy of 
psychological interventions for anxiety was undertaken. This was due to no individual 
patient data on a primary outcome of anxiety being available. All studies primary aim 
was to reduce depression symptoms in PWE and all used a form of CBT as their 
intervention. As the review found limited efficacy for this intervention in PWE 
rationale was provided for exploring the scope of alternative psychological 
interventions for anxiety and depression in PWE.  
Building on these findings, chapter two details an empirical study exploring the utility 
of an alternative psychological model in explaining anxiety and depression in PWE, 
the Self-Regulatory Executive Function (S-REF) model (Wells & Matthews, 1994). 
This is a transdiagnostic model which states maladaptive metacognitive beliefs and 
processes are fundamental in the development and maintenance of emotional distress, 
such as anxiety and depression. The model has initial support for its applicability to 
anxiety and depression in PWE (Fisher, Cook & Noble, 2016, Fisher & Noble, in 
press). This study aimed to advance evidence for using the S-REF model with PWE 
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through comparing its explanative ability against, illness perceptions, a well-known 
theoretical model for anxiety and depression in PWE. 
The study was an online cross-sectional design and involved 457 participants. A 
detailed methods section explains the recruitment procedure, data collection and 
analytical process used in the study. This is followed by the results section which 
offered further support for the applicability of the S-REF model in anxiety and 
depression in PWE by showing metacognitive beliefs explained additional variance in 
anxiety and depression after accounting for the control variables, including illness 
perceptions. Also, the central principle of the S-REF model was supported regarding 
the mediational role of the cognitive attentional syndrome (CAS) between 
metacognitive beliefs and anxiety and depression. Limitations of the study are then 
acknowledged before the chapter finishes with a discussion of the implications of the 
findings.  
Both chapters were written with the intention of obtaining publication in the journal 
‘Epilepsy and Behavior’. As such the structure and format of the chapters adheres to 
the specific guidelines stated by this journal (Appendix 1).   
The author would like to make the reader aware that for the empirical paper in chapter 
two both cross-sectional and longitudinal data (three month follow-up) was collected 
from participants. However, only the cross-sectional data was used in the final stated 
analyses in the empirical paper. The original proposal for the study was to use 
longitudinal data to conduct a prospective test of the S-REF model. This would better 
establish causal inferences than a cross-sectional design. However, there was a low 
rate of response from participants at the second time-point which made solely using 
the cross-sectional data as the most justifiable option. The data collection process 
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highlighted the challenges of using longitudinal designs and has given the student 
investigator chance to reflect on how to reduce sample attrition in longitudinal 
designs in their future research. The unused longitudinal data will be considered by 
the student investigator and their supervisors for future analyses.  
In summary, through adopting two contrasting methodologies detailed here in two 
separate chapters the thesis achieved its aims of exploring psychological interventions 
for anxiety and depression in PWE, and in the process, added illuminating evidence. 
The findings demonstrate there was limited efficacy for the psychological treatments 
used in RCTs. Interestingly all RCTs used cognitive behavioural therapy (CBT), 
which is the most frequently recommended psychological intervention for anxiety and 
depression in PWE (Kerr et al., 2011). This suggests it is essential to explore the 
potential of alternative psychological approaches. This was achieved in chapter two 
where further support for the applicability of the S-REF model in anxiety and 
depression in PWE was found.  
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Abstract 
Purpose: Psychological interventions, such as cognitive behavioural therapy are 
recommended for PWE experiencing clinical levels of anxiety and/or depression.  
However, controlled trials of psychological interventions and subsequent systematic 
reviews have only focused on the relative efficacy and have neglected the absolute 
efficacy of interventions, thus leaving many questions of efficacy unanswered.  
Establishing the absolute efficacy of an intervention should be an integral component 
of evidence-based practice.  To address this limitation, an individual patient data 
review of the clinical significance of psychological interventions for PWE with 
anxiety and/or depression was conducted. 
Methods: Eight eligible trials were identified, five of which supplied individual 
patient data (IPD) by treatment condition on the primary outcome variable. A Reliable 
Change Index (RCI) was calculated for each trial and used to classify if the symptom 
change demonstrated by each individual represented a ‘reliable improvement’ 
(treatment responders), ‘no reliable change’, or a ‘reliable deterioration’ on the 
primary outcome measure. 
Results: The overall rate of treatment responders across studies was low, with an 
average of 24% for those individuals defined as treatment completers. The percentage 
of treatment responders between studies ranged from 6% to 37%. The majority of 
individuals made no reliable change after intervention, with an average of 74% across 
studies (range 58-94%). An average of 2% of individuals across studies made a 
‘reliable deterioration’ post intervention (range 0%- 6%). There was a calculation of 
the absolute efficacy of psychological interventions for depression but not for anxiety 
as no individual patient data on a primary outcome of anxiety was available. 
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Conclusion: The findings indicate that psychological interventions are of limited 
efficacy for depression in PWE. The efficacy of psychological interventions for 
anxiety in PWE remains less clear, as it was not possible to calculate this in this 
study. All studies in the review used a form of cognitive behavioural therapy.  
Alternative psychological approaches for anxiety and depression in PWE should be 
explored, potentially using CBT as the control condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords 
Epilepsy, anxiety, depression, clinical significance  
10 
 
1. Introduction 
Anxiety and depression are common co-morbid conditions for people with 
epilepsy (PWE). Epidemiological studies report 9-37% of PWE meet diagnostic 
criteria for depression and 11-25% meet diagnostic criteria for an anxiety disorder [1]. 
Such figures may though underestimate the scale of the problem as several PWE 
experience subclinical levels of anxiety and depression [2]. It is now well known that 
the presence of anxiety and/or depression is associated with poorer outcomes. For 
instance, PWE experience a poorer quality of life (QOL) [3,4], more perceived 
epilepsy-related stigma [5], more suicidal ideation and are at an increased risk of 
suicide [6,7] compared to PWE without anxiety and/or depression. Furthermore, PWE 
who experience anxiety and/or depression respond poorer to surgical treatments for 
epilepsy [8], report more side effects of antiepileptic drugs (AEDs) [9], and are almost 
three times less likely to achieve seizure freedom with AEDs [10]. 
Psychological factors are consistently associated with anxiety and depression 
in PWE [11,12] and may be modifiable by psychological interventions. Cognitive 
behavioural therapy (CBT) is endorsed by the international consensus clinical practice 
[13] for the treatment of anxiety and depression in PWE. The National Institute for 
Health and Care Excellence (NICE) recommends CBT as a psychological 
intervention associated with improving the quality of life in PWE [14]. However, the 
evidence base for CBT and other psychological interventions is questionable. 
Ramaratnam, Baker & Goldstein’s Cochrane review [15] concluded there was 
insufficient evidence to support any type of psychological intervention for reducing 
emotional distress in PWE. Recent reviews are more optimistic and suggest 
psychological interventions elicit greater reductions in anxiety and depressive 
symptoms relative to control conditions [16-18].  
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A major limitation to date in terms of how interventions have been evaluated 
by both trials and subsequent reviews is that there has been an almost sole focus on 
the relative efficacy of a treatment when compared to control/comparator 
interventions, and a lack of consideration as to the clinical relevance of the change in 
symptoms. Relative efficacy is typically based on a comparison of group means and 
provides no information on the variability of response to interventions within a 
sample, such as the proportion of individuals in each condition who have deteriorated, 
not changed, and those who have improved or recovered [19]. A clinical significance 
analysis of treatments accounts for this through assessing both relative and absolute 
efficacy. This is essential to evidence based practice as it can provide clear evidence 
of treatment efficacy allowing clinicians and service users to make informed decisions 
about which interventions to choose [20,21].    
The most established method for determining the clinical significance of 
interventions is that of Jacboson and colleagues [22,23]. According to such criteria, 
for an individual to be classed as having recovered or demonstrated a clinically 
significant change in the target symptoms, the individual’s scores on the outcome 
measure of choice must meet two criteria: i) the change in symptom level from pre- to 
post-treatment must be ‘statistically reliable’, i.e. beyond that which could be 
accounted for by measurement error , and ii) their post treatment outcome score must 
be in a range that renders them indistinguishable from a ‘well’ population.   
A cursory examination of the baseline levels of distress of PWE in some trials 
of psychological intervention [24,25] shows there is substantial variability. Many 
trials have not had explicit inclusion criteria with regards baseline distress and have 
included PWE who were not clinically distressed upon recruitment, as well as PWE 
who were. This may explain why some studies have not examined the clinical 
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significance of the change elicited by interventions in their trials because, as outlined 
above, to qualify as clinically significant Jacobson’s criteria requires the change be 
reliable, but also be sufficient to move the persons score from a ‘clinically unwell’ 
population to that of a ‘well’ population.  
The variability in baseline distress levels of participants in the trials limits 
examinations of the relevance of symptom change associated with psychological 
interventions for PWE. It is though possible to begin to gauge the level of change by 
seeing to what extent the change in symptoms is, according to Jacobson’s first 
criteria, statistically reliably. Specifically, having obtained individual patient data 
(IPD) from the original trial, one can determine for which participants their change in 
symptoms was beyond that which could be accounted for by error associated with the 
outcome measure. It can then reliably calculate the proportion who can be defined as 
‘treatment responders’ (those that demonstrated a ‘reliable improvement’), those who 
show ‘no reliable change’, and those who show a ‘reliable deterioration’ on an 
outcome measure. Using these methods, this review aimed to establish the absolute 
efficacy of psychological interventions for anxiety and depression in PWE. This 
would help provide more conclusive evidence, which in turn will help inform clinical 
guidelines for treating anxiety and depression in PWE. 
2. Method 
The review followed guidance set out in the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) [26]. 
2.1. Study selection  
Medline, PsycINFO, PsycARTICLES, CINAHL plus, AHMED, 
clinicaltrials.gov, EThOS and SIGLE were searched from inception to March 2017 
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using Medical Subject Headings (MeSH) terms and keywords to identify 
psychological intervention trials for anxiety and depression in PWE. Combinations of 
terms associated with psychological interventions, emotional distress, and epilepsy 
were used. The final search strategy used for PsycINFO (Table 1) was adapted for 
each electronic database. To ensure a comprehensive search, reference lists and 
relevant meta-analyses were hand-searched for additional studies.  
Table 1: PsycINFO search terms  
Order Search term 
1. epilep* 
2. AND depress* OR anxi* OR mood OR 
‘quality of life’ 
3. AND therap* OR interven* OR treat* 
OR rehab* OR psycho*OR cognitive* 
4. AND trial OR random* 
 
To be included studies had to meet the following criteria: 
1. Random assignment to two or more psychological treatments or control conditions. 
2. They involved PWE aged 18 or above. 
3. They used a standardised outcome measure of anxiety and/or depression as their 
primary outcome. 
To obtain IPD the lead authors in the studies that met inclusion criteria were 
contacted by e-mail (Appendix 2). If no reply was received after three weeks a second 
e-mail was sent. After this, an attempt was made to contact the other authors in the 
studies by e-mail. 
2.2. Data extraction  
A data extraction form was developed to extract relevant characteristics and 
data (Appendix 3). This included sample demographics, treatment conditions, 
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inclusion criteria, attrition rate and an analysis of group x time interaction for the 
outcome measures.  
2.3. Quality assessment 
The PEDro-P scale [27] (Appendix 4 and 5) quality assessment tool was 
utilised to evaluate the methodological rigour and guide interpretation of the 
reliability and validity of results. The PEDro-P is a version of the PEDro scale which 
was modified specifically for the analysis of treatment trials for neurological 
disorders. The original PEDro scale is based on the Delphi list developed by 
Verhagen et al. [28]. It has demonstrated reliability for assessing RCT quality [29] 
and was used in a recent systematic review of psychological treatments in PWE [16]. 
The scale contains one question assessing external validity and ten assessing internal 
validity, all items are scored as yes (1) or no (0) to give an overall trial quality score. 
A second reviewer (PHR) undertook the study selection, data extraction and 
quality assessment. In the study selection process, after the lead investigator had 
initially excluded studies through screening titles and abstracts the second reviewer 
independently assessed the remaining studies against the inclusion criteria. Using the 
same measures as the lead investigator the second reviewer performed the data 
extraction and quality assessment processes on a random selection of 50% of the 
studies that were deemed eligible. The lead investigator and second reviewer cross-
checked results and inconsistencies were resolved. It was pre-agreed unresolved 
inconsistencies would be adjudicated by a third reviewer. 
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2.3. Clinical significance analysis 
          Jacobson’s reliable change index (RCI) [22,23] was utilised. The RCI was 
calculated using the following formula for each study: 
   where      and   
         An RCI greater than ±1.96 is required for reliable change [22,23], change 
exceeding 1.96 times the standard error is unlikely to occur no more than 5% of the 
time by unreliability of the measure alone. Waitlist data were also analysed to offer 
baseline estimates of the degree of improvement due to factors other than therapy, 
such as spontaneous recovery or regression to the mean.
RCI =
X2 - X1
Sdiff Sdiff = 2SE
2 SE = S1 1- rxx( )
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3. Results 
3.1. Study selection 
           The search retrieved 1280 studies (Figure 1). An additional three papers were 
identified through hand search. After removal of duplicates, 580 remained for screening 
based on title and abstract. Of these, 564 clearly did not meet the inclusion criteria. The full 
text articles of the remaining 16 studies were retrieved and assessed against the inclusion 
criteria. Eight studies were excluded for reasons shown in Figure 1, there were no 
inconsistencies in the main investigator and second reviewer’s study selections.  
           As of March 2017, eight studies were eligible for inclusion. Of these eight studies, 
only five studies provided individual patient data, these are described in Table 2. Individual 
patient data for the following studies was not made available by the original investigators: 
1. Davis, Armstrong, Donovan and Temkin [30] 
2. Tan and Bruni [31] 
3. McLaughlin and McFarland [32] 
These studies are described in Table 3. 
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3 additional studies identified 
through reference lists of papers 
580 studies screened (after 
duplicates removed) 
564 studies excluded as irrelevant 
after screening titles and abstracts 
5 studies included in analysis 
16 studies assessed for eligibility 
8 studies excluded against 
inclusion criteria: 
- Non-psychological intervention 
(n=2) 
- Contained participants <18 years 
old (n=1) 
- No primary measures of anxiety 
or depression (n=5) 
 
8 eligible studies 
3 studies excluded due to authors 
not providing individual patient 
data 
 
Figure 1 PRISMA diagram summarising the screening process for the included studies 
1280 studies identified using 
search terms in databases: 
Medline: 737 
Psychinfo: 421 
Cinahl Plus: 111 
Psycharticles: 1 
Ahmed: 3 
Clinical Trials.gov: 7 
Ethos: 0 
Sigle: 0 
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Table 2 
Characteristics of studies included in the review 
Author ( year, 
country),  
 
Conditions (type, delivery, dosage) 
 
Sample: (size), (age 
mean years, S.D), 
female % 
Inclusion criteria 
(epilepsy criteria, 
baseline distress level, 
age)   
Attrition % Primary measure of 
depression or anxiety 
(when measured, group 
x time interaction effect 
size, sig) 
Thompson et 
al.[24] (2010, 
U.S.A) 
 
CBT + M  (group therapy, phone or internet 
delivery by layperson with epilepsy and RA , 8x 
1 hour sessions,)   
 
CBT +M: (n=26), (36.4, 
34), 77% 
(One year post DX, 
scores on CES-D =  
>13 - <38,  >21 years 
old 
 
CBT +M = 25% mBDI (baseline-post, F 
int = 11.99, P =0.01) 
 TAU TAU: (n= 27), (35.4, 
31), 85%. 
 TAU =25%  
 
Ciechanowski 
et al. [25] 
(2010, U.S.A) 
 
 
CBT (individualised face-to-face, home 
delivery by 2 SWs, 8 x 50 minute sessions) 
 
CBT: (n= 40), (43.4, 
11.0), 47.5% 
 
(ICD-9 criteria, scores 
on PHQ-9 =  >10, >18 
years old) 
                              
CBT, post = 20%,      
12 month FU = 12.5%, 
18 month FU =25% 
                                       
 
 
HSCL-20 (baseline- 
post, t =1.70, p=0.09, 
baseline- 12 month FU, t 
= 3.15, p =0.003, 
baseline-18 month FU, 
wald x²= 4.00, P=0.046) 
 
                                                  
 TAU TAU: (n= 40), (44.4, 
11.1), 57.5% 
 TAU, post = 17.5%1  2 
month FU =  30%, 18 
month FU = 30% 
 
 
Schroeder et 
al. [33] (2014, 
Germany) 
 
 
CBT + M + ACT (individualised, online 
simulated dialogue, 9 weeks) 
                                 
CBT + M + ACT:  (n= 
40), (40, 1.85), 80% 
                                       
 
(Self-reported epilepsy 
and depression 
symptoms on the 
PESOS,  >18 years 
old)  
                                                  
                                   
                                
CBT = 27%, 
 
 
BDI (baseline-post, d = 
0.46, p = 0.01) 
 WLC WLC: (n =38), (35, 
9.99), 71%    
 WLC = 20%  
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Gandy et al.  
[34] (2014, 
Australia) 
CBT (individual face-to-face, delivered by 
psychology doctorate students, 9 x1 hr sessions) 
CBT: (n=31), (41, 12), 
50% 
 
(ILAE criteria, scores 
on the NART = >80, 
>18- <65 years old) 
CBT= 39% NDDI-E (baseline-post, 
d = 0.6, p = 0.045, 
baseline- 3 month FU, 
d= .39, p= 0.134) 
  
WLC 
 
WLC: (n=28 ), (38 , 13), 
76% 
  
WLC = 11% 
 
 
Thompson et 
al. [35](2015, 
U.S.A) 
 
 
CBT + M (group therapy, phone or internet 
delivery by layperson with epilepsy and RA, 8x 
1 hr sessions)  
 
 
CBT +M: (n=64), whole 
sample age = (41, NR), 
whole sample females = 
65.3 %. 
 
                                    
(Three months post 
DX, scores on CES-D  
= >8 - <27, >21 years 
old) 
 
 
CBT +M = 36% 
 
mBDI (baseline-post, F 
int = 4.67, P =.036) 
 TAU TAU: = (n = 64)  TAU = 12.5%  
ACT, Acceptance and Commitment Therapy; BDI, Beck Depression Inventory; CBT, cognitive behavioural therapy, CES-D, Center for Epidemiological Study of 
Depression measure; DX, diagnosis  FU, follow-up;  HSCL-20, Hopkins Symptom Checklist-20; ICD-9, International Classification of Diseases Ninth Revision; ILAE, 
International League Against Epilepsy; M, mindfulness; mBDI, Modified Beck Depression Inventory;  NART, National Adult Reading Task; NDDI-E, Neurological 
Disorders Depression Inventory for Epilepsy; NR, not reported;   PESOS, Performance Sociodemographic Aspects Subjective Estimation; PHQ-9, Patient Health 
Questionnaire-9; RA, research assistant; SWs, Social Workers; TAU, treatment as usual; WLC ,waitlist control. 
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Table 3  
Characteristics of eligible studies not supplying individual patient data 
Author ( year, country),  
 
Conditions (type, 
delivery, dosage) 
 
Sample: (size), (age mean 
years, S.D), female % 
Inclusion criteria 
(epilepsy criteria, baseline 
distress level, age)   
Attrition % Primary measure of 
depression or anxiety 
(when measured, group x 
time interaction effect 
size, sig) 
Davis et al. [30] (1984, 
U.S.A) 
 
CBT  (group therapy, 
delivered by 2 SWs, 6x 2 
hour sessions,)   
 
CBT: (n=8), age = 
(33.5,11), females = 
87.5% 
(NS, self-reported 
depression symptoms,  
>18 years old) 
CBT  = 0% DACL (baseline-post, NS, 
‘non-significance’ 
reported) 
 WLC WLC: (n= 5), age = (32.4, 
9.5), females = 60% 
 WLC =10%  
  
Tan and Bruni [31] 
(1986, U.S.A) 
 
 
CBT (group therapy, 
delivered by CP, 8 x 2 
hour sessions) 
 
CBT: (n= 8), total sample 
age = (33.4, 11.1), 
females = 62.5% 
 
(Confirmed DX, 
depression symptoms on 
GRPA-T—GRPA-N, 
GRPA –P , >18 years old 
                                    
CBT = 20%,  
                                       
 
 
BDI (baseline-post, NS, 
‘non-significance’ 
reported) 
                                                  
 AP (group supportive 
counselling, delivered by 
CP, 8 x 2 hour sessions) 
AP (n= 10), females = 
60% 
 AP = 0%  
  
WLC 
 
WLC: (n= 9), females = 
67% 
  
WLC = 10%% 
 
 
McLaughlin and 
McFarland [32] (2011, 
Australia) 
 
CBT (group, delivered by 
CP, 6 x2 hour sessions) 
                                     
CBT  (n= 18), age = 
(67.56, 7.27), females = 
56% 
                                       
 
(Confirmed DX, self-
reported depression 
symptoms and >24 on 
MMSE, age of  >60                                                  
                                   
                                    
CBT = 0%, 
 
 
GDS (baseline-post, NS, 
‘non-significance 
reported, baseline-3 month 
FU, NS, ‘non-
significance’ reported) 
 TAU TAU: (n =19), age = 
(67.37, 7.46), females = 
47%    
 TAU = 0%  
AP, attention placebo; BDI, Beck Depression Inventory; CBT, cognitive behavioural therapy;  CP, Clinical Psychologist; DACL, Depression Adjective Checklist form E; 
DX, diagnosis; FU, follow-up; GDS, Geriatric Depression Scale; GRPA, Global Ratings of Psychological Adjustment; T—Therapist; N—Neurologist; P—Patient; MMSE, 
Mini Mental State Examination; NS, not stated; SWs, Social Workers; TAU, treatment as usual;  WLC ,waitlist control.
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3.1. Study characteristics  
           Table 2 summarises the characteristics of the five studies in the review. One study [25] 
had a long term follow-up published in a separate study [36]. The studies included a total of 
384 participants (initially allocated to studies). The average number of participants in each 
study was 76.8 (SD: 32.4, range: 45-128). Most participants across the studies were female 
(n=257; 67%) with a mean of 68% per study (range: 53%-81%). Participants mean age was 
39.4 years (SD: 3.41).  
          Each study’s primary aim was to reduce depression symptoms using a psychological 
intervention. The outcome measures utilised to assess this were the Beck Depression 
Inventory (BDI) [37] by Schroeder et al. [33], the Hopkins Symptom Checklist-20 (HSCL-
20) [38]  by Ciechanowski et al. [25], the Neurological Disorders Depression Inventory for 
Epilepsy (NDDI-E) [39] by Gandy et al. [34] and a Modified Beck Depression Inventory 
(mBDI) [40] by Thompson et al. [24,35]. No study’s primary aim was to reduce symptoms of 
anxiety, one study had a secondary outcome measuring anxiety [34]. On average, post 
treatment outcome measures were administered 12 weeks (range: 8-26 weeks) after 
administering baseline outcome measures. The average attrition rate at first ‘post condition’ 
outcome measure was 23% (SD: 9.7, range: 11%-36 %).    
           To meet eligibility, some studies required participants to have epilepsy conditions 
according to International Classification of Diseases, Ninth Revision (ICD-9) [41] criteria 
[25], another specified International League Against Epilepsy (ILAE) [42] criteria [34] . 
Other studies stated participants were at least three months [35] or at least one year post 
epilepsy diagnosis [24]. One study [33] required participants to have epilepsy validated by 
the Performance Sociodemographic Aspects Subjective Estimation (PESOS) [43] 
questionnaire. All studies stated baseline levels of depression required for eligibility. 
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Ciechanowski et al. [25] required participants to have clinically significant depression 
validated by the Patient Health Questionnaire-9 (PHQ-9) [44].  Thompson et al. (2010) [24] 
used the Center for Epidemiological Study of Depression measure (CES-D) [45] to identify 
those with major depressive disorder and exclude those with severe depression. The CES-D 
was used again by Thompson et al. in 2015 [35] to specify participants with mild-moderate 
symptoms and exclude those with moderate-severe symptoms of depression. Schroeder et al. 
[33] included participants with any self-reported depression symptoms on the PESOS 
questionnaire [43] and Gandy et al’s [34] participants did not require any symptoms of 
depression to be eligible. 
 3.2. Interventions 
           All studies comprised one control and one intervention arm. Each study used a form of 
cognitive behavioural therapy (CBT) for depression in their intervention arm. Thompson et al 
in 2010 [24] and in 2015 [35]  delivered CBT with mindfulness practices to a group via 
telephone or the internet compared against treatment as usual (TAU) group who were 
contacted weekly by study facilitators to control for interaction with the project staff. In the 
Thompson et al. 2010 [24] study TAU group, at baseline 33% of participants were 
undertaking psychotherapy and 37% were using antidepressants. This was not statistically 
significantly different to the intervention group (17% psychotherapy; 39% antidepressants). 
Thompson et al’s. 2015 [35] TAU group also contained participants in psychotherapy and/or 
using anti-depressant medication. No figures reported the frequency of this, although the 
authors did report no statistically significant differences between intervention and TAU 
groups at baseline on these variables. 
          Ciechanowki et al. [25] compared face-to-face CBT (labelled: Program to encourage 
active, rewarding lives for seniors: PEARLS) delivered in the participants home against a 
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TAU group. At baseline this TAU group contained 40% of individuals on antidepressants and 
17.5% on psychoactive drugs, this was not statistically different to the intervention group 
(37.5% on antidepressants, 17.5% on psychoactive drugs). However, the number of 
participants taking antidepressants likely increased in both groups during the study, as study 
protocol dictated the study’s psychiatrist should contact the neurologist of any participant 
showing no improvement on the primary outcome measures at 4-5 weeks to recommend 
starting or adjusting antidepressants. There were no reported figures on this. Gandy et al. [34] 
compared individualised face-to-face CBT delivered in a clinic against a waitlist control 
(WLC) group. Here 15% (intervention) and 17% (WLC) of each group were taking 
antidepressants at baseline. Schroeder et al. [33] used an online simulated dialogue technique 
to compare CBT with mindfulness and acceptance and commitment therapy (ACT) (labelled: 
Deprexis) against a WLC group.  Participants in both conditions were using another form of 
depression therapy (Intervention: 46%, WLC: 50%) and/or taking antidepressants 
(Intervention: 17%, WLC: 20%) at baseline.  
          Interventions were delivered by a research assistant and a layperson with epilepsy [24, 
35], psychology doctorate students [34] and social workers [25]. These facilitators received 
regular supervision from either a clinical psychologist [24,34,35] or a psychiatrist [25]. One 
study required no direct facilitation [33]. The mean amount of treatment sessions for each 
trial was 8.4 (SD: 0.54, range: 8-9), with an average of 8.1 hours treatment delivery per 
intervention (SD: 1.1, range: 6.4-9). 
3.3. Outcomes reported by studies- Relative efficacy 
          Four studies reported statistically significant differences in their primary outcome 
measures between intervention and control conditions from pre-post treatment, Thompson et 
al. [24] (mBDI, F int = 11.99), Gandy et al. [34] (NDDI-E, d=0.6), Schroeder et al. [33] 
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(BDI, d = 0.46;) and Thompson et al. [35] (mBDI, F int = 4.67). Ciechanowski et al. [25] 
reported statistically significant results at 12 month follow up (HSCL-20, t =3.15) which 
persisted to 18 month follow-up (HSCL-20, wald x²= 4.00) [39]. These results are stated in 
Table 3. 
3.4. Clinical significance analysis 
           Table 4 details the RCI calculation for each study and Table 5 contains the percentage 
of participants within each Jacobson treatment outcome at post treatment and follow-up. 
Across studies, on average 23.5% (range: 6.3%- 36.8%) of participants were treatment 
responders, 2.2% (range 0%-5.8%) made reliable deterioration and 74.3% (range 57.8%-
93.7%) made no reliable change post-treatment. 
           When considering studies separately, Thompson et al. [24] achieved the highest rate of 
treatment responders (36.8%), followed by Schroeder et al. [33] (28%), Gandy et al. [34] 
(25%), Thompson et al. [35] (21.2%) and finally Ciechanowski et al. [25] (6.3%). The 
percentage of participants classed as making no reliable change post-treatment condition was, 
in descending order, Ciechanowski et al. [25] (93.7%), Gandy et al. [34] (75%), Thompson et 
al. [35] (73.1%), Schroeder et al. [33] (72%) and Thompson et al. [24] (57.8%). 
           Two studies reported follow-up data, Ciechanowski et al’s. [25] rate of treatment 
responders in their treatment condition rose slightly at both 12 month (9.7%) and 18 month 
[36] (7.7%) follow-up, as did Gandy et al’s [34] treatment condition at three month follow up 
(26.3%). Two studies contained participants who reliably deteriorated post treatment, 
Thompson et al. [24] (5.3%) and Thompson et al. [35] (5.8%). TAU conditions showed 
treatment responder rates of 28.8% [24], 5.4% [35] and 3% [25] and WLC conditions rates of 
8% [34] and 6.2% [33]. 
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Table 4                                                                                                                                                                                                                                                             
Data used to determine the RCI for each primary outcome for each study 
Symbol Definition                                                                     Measure: 
                                                                                     Author: 
                                                                                       
                                                                                          N 
mBDI [40] 
Thompson et al.  
[24] 
40 
HSCL-20 [38] 
Ciechanowski et al. 
[25] 
65 
BDI [37] 
Schroder et al. 
[33] 
57 
NDDI-E[39] 
Gandy et al.  
[34] 
45 
mBDI [40] 
Thompson et al.  
[35] 
108 
       
S1 Standard deviation for sample at pre-treatment 12.50 0.6   10.37         3.58 9.41 
X1 Pre-treatment score of an individual - - -       - - 
X2 Post-treatment score of an individual - - -       - - 
rxx Reliability of the scale       0.88
†
 0.85
††
     0.86*         0.85
**
    0.88
†
 
SE Standard error of measurement for the scale 4.33 0.55   3.88       1.38 3.25 
Sdiff Standard error of difference between the two test scores 6.12 0.77   5.48      1.96 4.60 
RCI Reliable change index 12.00 1.52    10.75       3.84 9.02 
BDI, Beck Depression Inventory;  HSCL-20, Hopkins Symptom Checklist-20;  mBDI, Modified Beck Depression Inventory, Mindfulness; NDDI-E, Neurological Disorders 
Depression Inventory for Epilepsy.  
†
 Internal consistency for mBDI [40]
  
††
 Internal consistency for HSCL-20 [38] 
* Internal consistency for BDI [37] 
** Internal consistency for modified NDDI-E  [39]
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Table 5 
Participants allocated to Jacobson categories at post-treatment and follow-up 
Study 
Treatment 
Pre-post 
treatment* 
   Pre- to 
follow-
up** 
   Pre- to 
follow- 
up*** 
   
 N No 
change 
(%) 
Deteri-
orated 
 
 
Improved N No 
change 
Deteri-
orated 
 
Improved N No change Deteri-
orated 
 
Improved 
Thompson et al. 
[24] 
            
CBT + M 19 57.8 5.3 36.8         
TAU 21 66.6 4.8 28.8         
Ciechanowski et al. 
[25] 
            
CBT 32 93.7 0 6.3 31 90.3 0 9.7 26 92.3 0 7.7 
TAU 33 93.9 3 3 28 100 0 0 26 96.2 3.8 0 
Schroeder et al.  
[33] 
            
CBT + M + A 25 72 0 28         
WLC 32 90.6 3.1 6.2         
Gandy et al.  
[34] 
            
CBT 20 75 0 25 19 73.7 0 26.3     
WLC 25 80 12 8 23 78.3 8.7 13     
Thompson et al. 
[35] 
            
CBT + M 52 73.1 5.8 21.2         
TAU 56 87.5 7.1 5.4         
             
* Thompson et al. [24,35]- 8 weeks, Schroeder et al. [33]- 9 weeks, Gandy et al. [34]- 2 months, Ciechanowski et al. [25]- 6 months 
** Gandy et al. [34] - 3 months, Ciechanowski et al. [25]- 12 months 
*** Chaytor et al. [36] – 18 months  
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3.4. Quality assessment 
          The results of the quality assessment are detailed in table 6. All studies scored one for 
external validity, as all specified eligibility criteria. The average internal validity score was 6 
(range 5-7) which is classed as ‘fair quality’ [27]. All studies used random allocation methods 
and concealed treatment allocation. Only two studies used blind assessors [25,33] and none 
of the studies blinded participants or therapists. All studies reported a statistical comparison 
of interventions between groups and reported point measures and measures of variability. All 
of the studies had an attrition rate during treatment above 15% in at least one of their 
conditions. Only one study [24] did not report an intention to treat analysis.  
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Study 
reference  
Eligibility 
criteria 
specified  
Subjects  
randomly 
allocated 
Treatment 
allocation 
concealed 
Groups 
similar at 
baseline 
Blinding of 
subjects 
Blinding of 
therapists 
Blinding of 
assessors 
Measures 
obtained 
from more 
than 85% 
of  subjects 
initially 
allocated to 
groups 
Subjects 
received 
treatment 
as allocated 
or data 
analysed 
by 
‘intention 
to treat’ 
Between-
interventio
n group 
statistical 
comparison
s reported  
Point 
measures 
and 
measures 
of 
variability 
reported 
Total score 
Thomspon 
et al. 
(2010) 
(24) 
Yes Yes Yes Yes No No No No No Yes Yes 5 
Ciechanow
ski et al. 
(2010) (25) 
Yes Yes Yes Yes No No Yes No Yes Yes Yes 7 
Schroeder 
et al. 
(2014) (33) 
Yes Yes Yes Yes No No Yes No Yes Yes Yes 7 
Gandy et 
al. (2014) 
(34) 
Yes Yes Yes Yes No No No No Yes Yes Yes 6 
Thompson 
et al. 
(2015) 
(35) 
Yes Yes Yes Yes No No No No Yes Yes Yes 6 
Table 6 
Quality assessment results 
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4. Discussion 
           Although recent systematic reviews exploring the efficacy of psychological 
interventions for anxiety and depression in PWE suggest that psychological treatments can 
help alleviate emotional distress [16-18], these suggestions are based on the relative efficacy 
of treatment compared to control conditions. As yet, the absolute efficacy of psychological 
treatments for emotional distress in PWE have not been reported. In consideration of this 
Jacobson and colleagues [22,23] clinical significance criteria was applied to psychological 
interventions for anxiety and depression in PWE. Specifically, the reliable change index 
(RCI) was used to calculate the proportion of individuals who can be defined as i) ‘treatment 
responders’ (those that demonstrated a ‘reliable improvement’), ii) showing ‘no reliable 
change’, and iii) showing a ‘reliable deterioration’, on each studies primary outcome 
measure. As most studies did not specify clinical levels of emotional distress as an inclusion 
criteria, it was not possible to determine if participants were more likely to have scores from 
a ‘well’ population following therapy.   
           Results showed the majority of PWE in psychological treatment conditions could not 
be classified as treatment responders. The amount of treatment responders ranged from 
36.8% in a telephone/internet group delivered CBT and mindfulness intervention [24] to 
6.3% in an individualised face-to-face CBT intervention [25].  Most individuals showed no 
reliable improvement after treatment (average 74.3% per study) and most showed no reliable 
deterioration following treatment (average 2.2% per study). Differences in the percentage of 
participants within each Jacobson category were found across studies. The two studies with 
most treatment responders used CBT and mindfulness [24] and CBT and mindfulness and 
ACT [33]. These studies adopted virtual methods of delivery, which in terms of accessibility 
are particularly advantageous for PWE, considering many are restricted from driving due to 
seizure activity. Also, virtual methods may be more cost effective for services and service 
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users and may reduce the fear of stigmatisation that PWE have in entering therapy [46]. In 
support of this, the studies using virtual methods had lower attrition rates than a clinic based 
face-to-face intervention [34]. 
          An intervention delivered in a group format yielded the highest percentage of treatment 
responders [24]. However, when the intervention was repeated the percentage of treatment 
responders dropped [35]. A potential factor contributing to this was difference in group size, 
as this was larger in the study with higher treatment responders. The group interventions were 
the only studies containing participants who reliably deteriorated post treatment; Thompson 
et al in 2010 [24] (5.3% deteriorated) and 2015 [35] (5.8% deteriorated). Potentially, group 
factors such as participants feeling isolated and receiving less individual support may have 
contributed to this.  
           The one study that required participants to meet a clinical threshold for depression 
produced the lowest rate of treatment responders [25]. Due to only two studies supplying 
follow up data, where one was a short-term follow up [34] and one potentially augmented 
their intervention with antidepressant medication [25] it is difficult to make conclusions 
regarding the sustainability of therapeutic effects. Considering all studies used a form of CBT 
and had low rates of treatment responders, results here add little support for CBT as an 
intervention method for PWE. Individualised face-to-face CBT is generally the most 
recognised method of delivery in services, however studies using this method showed only 
6.3% [25] and 25% [34] of their participants were treatment responders.  
           Confidently attributing the therapeutic modality factors just mentioned to the 
correlation of results is compromised due to several confounding variables in the studies. For 
instance, across studies there were different epilepsy and depression classifications, 
participants receiving antidepressants or alternative therapy for psychological difficulties, 
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varying lengths of intervention delivery and varying professions as treatment facilitators. As 
mentioned, none of the studies used diagnostic criteria for depression as inclusion criteria. 
Rather, different levels of clinical severity of symptoms were used in three studies [4,24, 
25,35] one [33] only required participants to report that they had depressive symptoms and 
the final study [34] did not require participants to have any depressive symptoms. Therefore, 
it is difficult to directly compare between studies which had different thresholds based on 
different symptom measures. For example, participants with low levels of depression have 
less scope to show statistically reliable improvement, which could lead to an underestimation 
of treatment efficacy.    
            Having studies which assess the impact of psychological treatments for PWE with 
relatively few symptoms is important, considering having low levels of emotional distress 
can contribute to poor QoL in PWE [2]. However, results of such studies may lack clinical 
relevance and not translate to evidence based clinical services where treatment may only be 
provided to patients with clinical levels of emotional distress, coupled with the fact that the 
psychological interventions for this group of patients was only marginally better than control 
conditions [25].  
         As discussed, due to factors within the included studies in this review our analysis of 
absolute efficacy was restricted to reporting on the proportion of participants that made 
statistically reliable change based on the RCI. This is a less stringent analysis of clinical 
significance as solely using the RCI does not allow recovery rates to be estimated, only 
treatment response [21]. Also, statistically reliable change based on the RCI for those with 
low levels of symptoms at baseline may not be clinically meaningful as the opportunity for 
improvement is minimal, although it does allow deterioration over the course of treatment to 
be assessed [21].  
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The methodological quality of the included studies was somewhat limited, with an average 
rating of “fair” across the studies based on the PEDro-P scale [27]. The studies had large 
attrition rates, with a mean of 23% (range: 11%-39%) per study and only two studies 
systematically evaluated the characteristics of those who dropped out [33,34]. Three of the 
five studies did not use blind assessment [24,25,35] and none of the studies used blinded 
subjects or therapist, which increases the risk of bias [47].  There were also no operational 
definitions provided to classify participants who completed an adequate dose of therapy. The 
methodological quality of studies found here concords with previous reviews in the area [15-
18]. Additionally, the studies were relatively small and females were over represented in all 
of the studies by up to 30% when compared to the wider epilepsy population [48]. Whether 
this higher representation of females in the studies is representative of PWE who access 
mental health services remains inconclusive, as no statistics were found to evidence this. 
Although, large-scale research exploring gender differences and anxiety and depression 
symptoms in PWE showed females had significantly greater depression symptoms. 
           The review also extracted and considered the relative efficacy of treatments. All 
included studies on at least one time-point, showed intervention groups with statistically 
significant reductions in their symptom levels when compared to a control condition. 
Considering this alone (discounting the analysis of clinical significance) would uphold the 
optimism in previous reviews and offer evidence to support psychological interventions as 
efficacious for depression in PWE, particularly as this review encompassed three studies 
undertaken subsequently to the aforementioned reviews. However, when absolute efficacy is 
explored through using the RCI these conclusions are contradicted. Jacobson et al. [19] 
argues forming conclusions based on small statistical effects of group differences is 
insufficient evidence of treatment efficacy and statistical effects must be supplemented with 
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reports of the clinical significance of treatment effects to determine if a treatment is 
efficacious. 
           The review was limited in that it included only five controlled studies, as three studies 
did not supply IPD, which restricts confidence in the conclusions. This highlights the limited 
amount of treatment outcome research conducted in this population. Including all eight 
studies in an analysis would have increased the generalisability of findings. This could have 
partially been achieved through subjecting the three studies which did not provide IPD to an 
analysis of their relative efficacy and their quality. Although this may have provided firmer 
conclusions in these areas, it was felt their inclusion within these analyses would deflect from 
the main focus of the review, which was to explore the clinical significance of psychological 
interventions using Jacobsen methodology. Including studies which did not provide IPD and 
were not assessed using Jacobsen methodology may have made interpretation of results more 
difficult and would not have allowed for a direct comparison of the absolute and relative 
efficacy of these studies. 
 The review was unable to assess the clinical significance of any psychological treatment for 
anxiety in PWE as none of the included studies had an anxiety measure as their primary 
outcome. Furthermore, the three studies where IPD was not available had no outcome 
measures of anxiety. This supports that there is a scarcity of research into anxiety in PWE 
[49] and it remains a neglected clinical issue [50].  
5. Conclusion 
         The review found limited support for the efficacy of psychological interventions in 
PWE. Although previous reviews have contradicted this conclusion, their evidence was based 
on solely reporting relative efficacy. Evidence here suggests this is not sufficient to evidence 
the efficacy of a treatment, as when exploring the absolute efficacy of psychological 
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treatments using Jacobson’s RCI  a low percentage of participants could be classed as 
‘treatment responders’. To make more conclusive deductions on the efficacy of psychological 
treatments for anxiety and depression in PWE, there is a need to conduct methodologically 
robust clinical trials with PWE that have clinical levels of emotional distress. Specifically, 
large RCT’s with an even gender spread are recommended with more rigorous delivery 
protocols. Unfortunately, the review was unable to analyse the clinical significance of 
psychological interventions for anxiety in PWE as there was no IPD for a primary outcome 
measure of anxiety available. It is essential that treatments look beyond depression and also 
focus on anxiety.  
          Overall, results imply there is substantial scope for improvements in psychological 
treatments for anxiety and depression in PWE. As all studies used a form of CBT, this 
improvement may be found through exploring alternative psychological approaches. 
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Abstract 
 
Purpose: Symptoms of anxiety and depression are common in people with epilepsy (PWE). 
However, evidence suggests the current psychological models and associated treatments for 
anxiety and depression for PWE are limited.  It is possible that there are other psychological 
models of anxiety and depression with greater clinical utility for PWE. The Self-Regulatory 
Executive Function (S-REF) model is a transdiagnostic model of emotional disorder which 
states maladaptive metacognitive beliefs and processes are fundamental in the development 
and maintenance of anxiety and depression. There is preliminary support for the applicability 
of the S-REF model to emotional distress in PWE. This study aimed to provide a more 
stringent test of the S-REF model through comparing its explanative ability against a more 
established theoretical model for anxiety and depression in epilepsy, namely, illness 
perceptions. It was specifically explored whether metacognitive beliefs explained additional 
variance in anxiety and depression after accounting for demographics, epilepsy 
characteristics and, illness perceptions. The mediational relationships between metacognitive 
beliefs, the cognitive attentional syndrome (CAS) and anxiety and depression, predicted by 
the S-REF model were also explored. 
Methods: Four hundred and fifty-seven PWE participated in an online survey and completed 
self-report questionnaires measuring anxiety, depression, metacognitive beliefs, illness 
perceptions and CAS processes. Participants also provided information on demographics, 
epilepsy characteristics and number of, and perceived side effects of, anti-epileptic 
medication.  
Results: Regression analysis showed that metacognitive beliefs explained additional variance 
in anxiety and depression after accounting for the control variables, including illness 
perceptions. The central principle of the S-REF model was supported; the relationship 
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between negative metacognitive beliefs about uncontrollability and danger of worry and 
anxiety symptoms was partially mediated by the CAS.   
Conclusion: Metacognitive beliefs and processes contribute to anxiety and depression in 
PWE more than illness perceptions, thereby providing further support for the utility of the S-
REF model.  Modifying negative metacognitive beliefs and the CAS using metacognitive 
therapy could alleviate anxiety and depression in PWE, this remains to be tested in future 
research. 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords 
Epilepsy, anxiety, depression, metacognitions, S-REF model, illness perceptions 
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1. Introduction 
Symptoms of anxiety and depression are commonly experienced by people with 
epilepsy (PWE). A review of epidemiological studies found 9-37% of PWE met the 
diagnostic criteria for depression and 11-25% met the diagnostic criteria for an anxiety 
disorder, and that they often co-exist [1]. Additionally, PWE frequently experience 
subclinical levels of anxiety and depression as evidenced by Mensah and colleague’s large 
scale studies. Using the Hospital Anxiety and Depression Scale (HADS) [2] they reported 
18.9% of their sample as having borderline anxiety and 20.5% meeting ‘caseness’ [3] and 
11.2% as having borderline depression and 16.6% meeting ‘caseness’ [4]. Anxiety and 
depression adversely affect the quality of life (QoL) of PWE, often to a greater degree than 
seizure frequency and severity [5] and the adverse effects of anti-epileptic drugs (AEDs) [6]. 
Barry et al. [7] believe it is imperative that clinical management of PWE should include 
screening for the presence of anxiety and depression, and once identified as clinically 
significant, effective interventions should be implemented. 
To best inform interventions, conceptualising which factors cause and maintain 
anxiety and depression in PWE is required.  Age [8], gender [9], socioeconomic status [10], 
marital status [11], employment status [12,13], education level [14], seizure frequency [15], 
and AEDs side effects [16] have all been purported to have a role. However, systematic 
reviews have concluded psychological factors as the most robust predictors of anxiety and 
depression in PWE [17,18], these factors may be modifiable via psychological intervention. 
Current psychological approaches to anxiety and depression in PWE focus largely on 
an individual’s cognitive representations of their epilepsy using the framework of Leventhal’s 
common-sense model (CSM) of self-regulation in health and illness [19]. Central to the CSM 
is the idea that an individual’s illness perceptions, i.e. their beliefs, attitudes and ideas about 
their illness) influence how they make sense of their symptoms, which in turn influences 
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coping strategies and determines outcomes such as psychological wellbeing, i.e. anxiety and 
depression. Leventhal, Benyamini and Brownlee [20] describe five main illness perceptions; 
(i) Identity: beliefs about the label and symptoms that individuals associate to the condition. 
Individuals are likely to interpret diverse symptoms as evidence of the label [21]. (ii) Cause: 
beliefs about the cause of the condition. (iii) Time-line: beliefs about the course of the 
condition (iv) Consequences: beliefs about the consequences of the condition and how it 
affects one’s life. (v) Curability/ controllability: beliefs about possible cures or effective 
management of the condition and the degree to which the individual can play a role in this. 
Studies with PWE have demonstrated that illness perceptions explain a greater proportion of 
the variance in emotional distress and an individual’s ability to cope with their condition than 
seizure-related variables [22-24]. 
Illness perceptions have played an important role in influencing psychological 
interventions, such as CBT [25]. However, evidence for the efficacy of CBT or any other 
psychological therapy for emotional distress in PWE is limited. A Cochrane review 
concluded there was insufficient evidence to support any psychological intervention for 
emotional distress in PWE [26]. Subsequent systematic reviews of randomised controlled 
trial (RCT) evidence have offered some support for psychological interventions in PWE, 
showing psychological intervention conditions yield statistically greater reductions in anxiety 
and depression symptoms compared to control conditions [27-29]. However, each review 
acknowledged their conclusions were restricted as they were based on few studies which 
contained several methodological limitations. Also none of the reviews explored the clinical 
significance of the studies. Currently, insufficient evidence exists to recommend any specific 
psychological intervention [30].  
Exploring alternative psychological models to those currently being used in PWE may 
identify modifiable psychological mechanisms involved in the development and maintenance 
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of anxiety and depression in PWE and could result in more effective interventions [31]. One 
candidate is the self-regulatory executive function model (S-REF) [32]. The S-REF model 
suggests that the presence of negative illness perceptions alone are insufficient to explain the 
development and maintenance of emotional distress. For example, most PWE will hold 
negative illness perceptions about their condition, but many of these will not experience 
anxiety or depression. The S-REF model proposes that it is how an individual responds to 
their negative illness perceptions that leads to emotional distress. The response style is termed 
the cognitive attentional syndrome (CAS).  The CAS consists of repetitive worry/rumination 
and maladaptive coping strategies such as threat monitoring, avoidance and thought 
suppression which perpetuates emotional distress and continued negative appraisal [33].   
The theory specifies that metacognitive beliefs, i.e. beliefs about the control and 
execution of cognition, determine whether the CAS is selected and implemented in response 
to the occurrence of a negative thought or illness perceptions. A broad range of metacognitive 
beliefs are specified in the S-REF model but they can be usefully separated into positive 
metacognitive beliefs and negative metacognitive beliefs about the uncontrollability and 
danger of worry. Positive metacognitive beliefs concern the benefits of engaging in each 
aspect of the CAS (e.g., ‘worrying about my symptoms, means I’ll cope more effectively). 
Negative metacognitive beliefs about the uncontrollability and danger of worry (e.g., ‘I can’t 
control my worry) maintain and increase worry and in turn increase levels of distress. In the 
S-REF model, negative metacognitive beliefs about the uncontrollability and danger of worry 
can occur anywhere in the worry process, i.e. they may occur at the start of the worry 
process, during worry or may be the outcome of worry.  However, negative illness 
perceptions alone are not considered to play a causal role in the emotional distress according 
to the S-REF model.   
47 
 
 
 
 As evidenced in systematic reviews CBT has been the most explored therapeutic 
modality for anxiety and depression in PWE [26-29]. There have been randomized controlled 
trials which have explored the effectiveness of alternative approaches of mindfulness [34,35] 
and mindfulness and acceptance and commitment therapy (ACT) [36] in combination with 
CBT. These showed interventions eliciting greater reductions in depressive symptoms 
relative to control conditions. Mindfulness and ACT encourage individuals to attend to 
difficult thoughts rather than avoid or attempt to suppress them. This allows the individual to 
link thoughts to the distress. Once an individual notices the thoughts, mindfulness and 
acceptance skills can be used to let them go and in the process, reduce distress. [37]. 
Potentially, utilizing ‘third wave’ approaches may be a more effective approach for PWE, as 
unlike CBT, they do not require individuals to engage with and test the content of negative 
thoughts about epilepsy, which for many PWE can be difficult as they are potentially 
accurate considering the threat of future seizures.  
The associated therapeutic intervention of the S-REF model, metacognitive therapy (MCT) 
utilises the premise of mindfulness but also focuses on modifying individual’s metacognitive 
processes. This approach was chosen as the therapeutic modality of choice for this study as it 
is an alternative ‘third wave’ approach which has been less extensively evaluated in PWE 
experiencing emotional distress. Also, preliminary studies have demonstrated that 
metacognitive beliefs are associated with anxiety and depression in PWE independently of 
demographic and epilepsy related variables, [38,39]. There is also extensive evidence 
supporting the role of metacognitive beliefs in anxiety and depression in mental health [40-
42] and other physical health populations [43-45]. 
This study aims to provide a further test of the S-REF model and its applicability to anxiety 
and depression in PWE through comparing its explanative ability against illness perceptions; 
a more established theoretical model for anxiety and depression in PWE. The S-REF model 
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predicts that metacognitive beliefs should account for variation in anxiety and depression 
beyond the variation attributable to demographics, epilepsy related variables and illness 
perceptions. The following hypotheses were tested:  
1) Metacognitive beliefs will explain additional variance in anxiety after controlling for 
demographics, epilepsy characteristics and negative illness perceptions in PWE.  
2) Metacognitive beliefs will explain additional variance in depression after controlling for 
demographics, epilepsy characteristics and negative illness perceptions in PWE. 
 3) As predicted by the S-REF model, the CAS will fully mediate the relationship between 
positive metacognitive beliefs and anxiety and depression, and partially mediate the 
relationship between negative metacognitive beliefs about the uncontrollability and danger of 
worry and anxiety and depression.  
2. Method  
2.1. Study design and participants 
The study was a cross-sectional design using an online survey. The University of 
Liverpool’s Research Ethics Committee approved the study (ref: RETH00103) (Appendix 6). 
All participants reported a clinical diagnosis of epilepsy (all syndromes and seizures types 
permitted) and were currently prescribed antiepileptic medication. All were aged ≥18 years. 
People were excluded if they could not provide informed consent or independently complete 
questionnaires in English.   
2.2. Procedure 
The online survey was conducted between July 2016 and February 2017.  Participants 
were recruited by advertisements (Appendix 7) placed in the newsletters and on the websites 
of epilepsy interest groups and organizations within England, Scotland, Wales, and the 
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Republic of Ireland (see acknowledgements). Individuals interested in taking part were 
directed to an online survey page hosted by Qualtrics. Here, participant information 
(Appendix 8) was given and permission for informed consent (Appendix 9) was sought.  
After completing the survey measures, participants were debriefed (Appendix 10) and offered 
the option to be entered into a ‘prize draw’ to win a £20 voucher.   
2.3. Measures 
2.3.1. Participant characteristics  
Participants reported their demographics and medical history (Appendix 11). The 
information asked for is detailed in Table 1. Of note, participants were asked to report on the 
number of seizures they had experienced in the prior 12 months, whether they were on AED 
monotherapy or polytherapy and whether they experienced AED side effects or not. 
2.3.2. Anxiety and Depression 
The Hospital Anxiety and Depression Scale (HADS) [2] (Appendix 12) was 
developed to measure both anxiety and depression in individuals with physical illness. It 
comprises seven items measuring depression and seven items measuring anxiety. Each item 
is scored on a 4-point scale, ranging from 0-3. This produces two separate total subscale 
scores for anxiety (HADS-A) and depression (HADS-D) ranging from 0-21. Scores of 0-7 
represent ‘normal’ levels of anxiety or depression, scores of 8-10 represent ‘borderline’ case 
levels, and 11-21 represent ‘case’ levels. The HADS has high sensitivity and specificity for 
anxiety and depression in PWE [36,37], and has demonstrated good internal consistency ( 
HADS-A, α =.80, HADS-D  α = .76 ) and stability, (test-retest intraclass correlation 
coefficient HADS-A = .90, HADS D = .84). Good internal consistency was found for the 
present sample ( HADS-A, α =.80, HADS-D  α = .83 )   
2.3.3. Metacognitive beliefs 
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The Metacognitions Questionnaire 30 (MCQ-30) [46] (Appendix 13) is a 30-item 
self-report questionnaire developed to assess participant’s metacognitive beliefs. Participants 
are presented with statements regarding metacognitive beliefs and asked to rate using a 4-
point scale (1 = do not agree, 2 = agree slightly, 3 = agree moderately, 4 = agree very much) 
how much they “generally agree” with that statement. Its 30 items are distributed equally 
onto the following five subscales: i)‘Positive beliefs about worry’ (Positive metacognitive 
beliefs) (e.g., Worrying helps me avoid problems in the future) ,ii) ‘Negative beliefs about the 
uncontrollability and danger of worry’ (Negative metacognitive beliefs) (e.g., My worrying 
is dangerous for me), iii) ‘Need to control thoughts’ (e.g., I should be in control of my 
thoughts all the time), iv)‘Cognitive self-consciousness’ (e.g., I pay close attention to the way 
my mind works) and, v) ‘Cognitive confidence’ (e.g., I have a poor memory). Total scores for 
the subscales range from 6 to 24, with a higher score representing a stronger belief in the 
items encompassing that subscale. The questionnaire demonstrated good internal consistency 
(α = .86) and good stability over time (test-retest intraclass correlation = .85) for assessing 
metacognitive beliefs in PWE [38]. Excellent internal consistency was found for the present 
sample (α = .90). 
2.3.4. Illness perceptions 
The Illness Perception Questionnaire-Revised (IPQ-R) [47] (Appendix 14) measures 
illness perceptions. It is divided into three sections. The first section, ‘identity’ asks 
participants to state their experience of 15 common symptoms since their diagnosis and if 
these are attributed to their condition. This section was not included in the study as the 
symptoms were not common to epilepsy. The second section comprises of seven illness 
perception subscales: ‘timeline (acute/chronic)’, ‘consequences’, ‘timeline cyclical’, 
‘emotional representations’, ‘personal control’, ‘treatment control’ and ‘illness coherence’. 
Each subscale contains up to 6 items, where each item is a statement which participants are 
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asked to rate on a 5 point scale (1 = strongly disagree, 2 = disagree, 3 = neither agree or 
disagree, 4 = agree, 5 = strongly agree) how much they agree with that statement. This yields 
a total score for each illness perception subscale. 
Higher scores on the ‘timeline (acute/chronic)’, ‘consequences’, ‘emotional 
representations’ and ‘timeline cyclical’ subscales signify a belief that a condition is chronic, 
that it has negative consequences including emotional effects and is cyclical in its nature. 
High scores on the ‘personal control’, ‘treatment control’ and ‘illness coherence’ subscales 
signify positive beliefs about the controllability of their condition and a good personal 
understanding of their condition. The final section of the questionnaire measures participants 
causal attributions of their condition and is scored on a five-point scale, this was not included 
in the study. Good internal consistency (α =.84) and moderate test-retest reliability (test-retest 
intraclass correlation coefficient =.60) have been demonstrated for the IPQ-R in epilepsy 
populations [48]. Moderate internal consistency was found for the present sample (α = .68). 
2.3.5. Cognitive Attentional Syndrome  
The Cognitive Attentional Syndrome Scale (CAS-I) [49] (Appendix 15) is a self-
report measure that assesses the core aspects of the CAS, including frequency of worry and 
rumination, counterproductive efforts at thought control and threat focussed action. The 
measure used was a 10-item questionnaire adapted from the 16-item original questionnaire. 
In this study only the first 6 items of the questionnaire were used and the last 4 items were 
discarded as they assessed metacognitive beliefs, which were more specifically measured 
using the MCQ-30. Each of the 6 included items refers to a core aspect of the CAS. 
Participants are asked to rate how much time in the preceding week they have engaged in 
these behaviours on an 11 point Likert scale ranging from 0 (none of the time) to 10 (all of 
the time). A total score is yielded from adding the 6 items, with a higher score indicative of 
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greater use of CAS behaviours. The CAS-1 has shown good internal consistency (Cronbach's 
α=.78) and significant positive correlations with anxiety and depression measures in clinical 
populations [49]. Good internal consistency was found for the present sample (α = .81). 
2.4. Analysis 
Descriptive statistics examined participants' characteristics and their experience of 
anxiety and depression.  Initially a missing value analysis was carried out revealing 35 
individuals had missing data, Little’s MCAR test on these values was not significant (Sig 
=.995), establishing these values to be missing completely at random. Subsequently, missing 
values were imputed in SPSS using the expectation maximization algorithm [50]. 
 To examine the hypotheses that metacognitive beliefs will explain additional variance 
in anxiety and depression in PWE after having controlled for demographics, epilepsy 
characteristics and illness perceptions, hierarchical linear regression was used. On step 1, age, 
gender, marital status (married/in a relationship vs not married/not in a relationship), 
employment status (employed vs unemployed) and education level (left school at 
‘O’level/GCSE vs further education), were entered. On step 2, participants’ seizure frequency 
in last 12 months, number of prescribed AED’s (monotherapy vs  polytherapy) and AED 
side-effects (yes vs no) were entered. On step 3; scores on the seven illness perceptions (IPQ-
R) subscales were entered and on step 4; scores on the five metacognitive beliefs (MCQ-30) 
subscales. The associated beta values from the regression were analysed to show how 
strongly each predictor variable influenced either anxiety or depression. A further regression 
reversed steps 3 and 4 to see if illness perceptions explained additional variance when 
demographics, epilepsy characteristics and metacognitive beliefs were controlled for. In all 
regressions either anxiety (HADS-A score) or depression (HADS-D score) were the 
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dependent variables. As these dependent variables were not normally distributed (Shapiro 
Wilk, p = 0.000), bootstrapping techniques were used to ensure findings were robust [51].  
 To explore the predicted mediation relationships between the CAS, metacognitive 
beliefs and anxiety and depression, four mediation analyses were conducted. All analyses 
controlled for the influence of illness perceptions, the untested metacognitive beliefs and 
demographic and epilepsy characteristics. As the data did not meet assumptions of normality 
bootstrapping methods were again applied to ensure robustness. Following recommendations, 
5,000 samples were used [52,53].  
 All analyses were undertaken using IBM SPSS Statistics v.24. [54] and the 
PROCESS macro [55]. 
3. Results 
3.1. Participants 
Four hundred and fifty seven participants took part, giving the study adequate power 
to detect an effect with a given degree of confidence (Appendix 16). Participants’ 
demographics and characteristics are detailed in Table 1. The sample’s mean age was 36.4 
years (SD = 12.4; range 18 to 73), 74.2% were female and the majority (95.4 %) identified 
themselves as being ‘white’. Fifty percent of the sample had a HADS-D score in the 
borderline or case range, whilst 84.5% had a HADS-A score in the borderline or case range. 
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3.2. Association between anxiety and depression and metacognitive beliefs  
 
Table 1 
Participant characteristics (n=457) 
Characteristic Category n (% of participants) 
Gender Male 118 (25.8%) 
 Female 339 (74.2%) 
Age: mean (range; SD)  36.4 (18-73; 12.4) 
Ethnicity  White 437 (95.4%) 
 Black or African American 1 (0.2%) 
 Asian 7 (1.5%) 
 Mixed ethnic origin 10 (2.2%) 
 Other 2 (0.4%) 
Residence  England 365 (79.9%) 
 Northern Ireland 13 (2.8%) 
 Republic of Ireland 17 (3.5%) 
 Scotland 39 (8.5%) 
 Wales 23 (5%) 
Marital status Married 167 (36.5%) 
 Not married 290 (63.5%) 
Highest educational qualification Post graduate university 77 (16.8%) 
 Under graduate university 158 (34.6%) 
 School education 196 (44.9%) 
 No qualifications 26 (5.7 %) 
Employment Full-time 141 (30.9%) 
 Part-time 81 (17.7%) 
 Self-employed 27 (5.9%) 
 Unemployed 81 (17.7%) 
 Retired 55 (20%) 
 Student 44 (9.6%) 
 Housewife/Househusband 28 (6.1%) 
Currently driving Yes 104 (22.8%) 
Age diagnosed, mean (SD)  19.2 (11.1) 
Seizure frequency past 12 months At least daily 21 (4.6%) 
 At least weekly 66 (14.4%) 
 At least monthly 128 (28%) 
 At least quarterly 51 (11.2%) 
 Less than quarterly 62 (13.6%) 
 None 129 (28.2%) 
Seizure types experienced* Single 184 (40.2% 
 Multiple forms 273 (60.8%) 
AED amount Monotherapy 197 (42.7%) 
 Polytherapy 260 (56.4%) 
AED side-effects Yes 342 (74.8%) 
Medical history beyond epilepsy Another medical condition 139 (30.4%) 
 A psychiatric condition 52 (11.4%) 
 A psychiatric and medical 
condition 
 
62 (13.6%) 
Anxiety (HADS-A, mean (SD)  11.7 (4.2) 
 Not anxious (score: 0-7)                                   61 (15.5%)
 Borderline (8-10) 104 (22.8%) 
 Caseness (11-21) 292 (61.7%) 
Depression (HADS-D), mean (SD)  7.9 (4.5) 
 Not depressed ( 0-7)                                   228 (49.9%) 
 Borderline (8-10) 102 (22.8%) 
 Caseness (11-21) 127 (27.2%) 
Note: SD= standard deviation, *some participants reported experiencing multiple forms of seizures, 
the amount of participants reporting experiencing each seizu s type w s as follows:  Simple focal 
seizures- 296; complex focal seizures- 278; absent seizures 230; tonic-clonic seizures 132.  
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3.3. Association between anxiety and depression and metacognitive beliefs  
  Results of the regression analysis are shown in Table 2 and the results of the 
regression analysis when steps 3 and 4 were reversed are shown in Table 3. After controlling 
for demographic variables, epilepsy variables and illness perceptions (which accounted for 
21% of the variance), metacognitive beliefs explained an additional 26% of the variance in 
anxiety scores (F change [5, 436] = 49.26, p=0.000). Together the final model explained 73% 
(adjusted R
2
 = 0.51) of variance with, in decreasing order of importance, the subscales 
‘negative metacognitive beliefs about the uncontrollability and danger of worry’ (MCQ-30), , 
‘emotional representations’ (IPQ-R), gender, marital status, ‘consequences’ (IPQ-R), and 
‘timeline (acute/chronic)’ (IPQ-R) making significant independent contributions to the 
model. When metacognitive beliefs subscales were entered into the model before illness 
perceptions subscales, metacognitive beliefs accounted for 43% of variance in anxiety scores 
(F change [5, 443] = 74.8, p=0.000) and illness perceptions added an additional 4% of 
variance ( F change [7,436] = 5.94, p = 0.000). 
          With depression as the dependent variable, after controlling for demographic variables, 
epilepsy variables and for illness perceptions (which accounted for 13% of variance), 
metacognitive beliefs explained an additional 13% of variance (F change [5, 436] = 16.95, 
p=0.000). The final model explained 58% (adjusted R
2
 = 0.31) of the variance, with, in 
descending order of significance, the subscales ‘negative metacognitive beliefs about the 
uncontrollability and danger of worry’ (MCQ-30), ‘need to control thoughts’ (MCQ-
30)’,’cognitive confidence’ (MCQ-30), ‘consequences’ (IPQ-R),  ‘treatment control’ (IPQ-
R), and ‘cognitive self-consciousness’(MCQ-30) making significant independent 
contributions to the model. When steps 3 and 4 were reversed metacognitive beliefs 
accounted for 22% of variance (F change [5, 443] = 27.16, p=0.000) and illness perceptions 
4% of variance in depression scores (F change [7, 436] = 4.1, p = 0.000).   
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In both regression models there was no indication of multicollinearity as correlations 
were not above 0.7 (Pearson’s r) between study variables, and collinearity statistics showed 
no figures greater than 1 in ‘tolerance’ or less than 10 in  ‘variance inflation factors’. 
Additionally, the Durbin-Watson test showed autocorrelation was not a factor with scores of 
2.01 (anxiety regression) and 2.11 (depression regression). 
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Table 2: Final models of the variance in anxiety and depression explained by metacognitive beliefs after controlling for 
demographics, epilepsy characteristics, and illness perceptions 
 Anxiety  Depression 
 R
2
  
change 
Beta T Sig  R
2
 
change 
Beta T Sig 
Demographics .04     .05    
 Age  -.07 -1.66 .139   .08 1.75 .105 
 Gender  -.10 -2.93 .007   .02 .38 .728 
 Employment status  -.04 -1.25 .198   -.09 -2.13 .401 
 Education level  -.02 .48 .650   -.01 -.16 .873 
              Marital status  -.10 -2.54 .017   .01 -.29 .779 
Epilepsy characteristics .01     .03    
 Seizure frequency 12 months  -.06 -1.43 .16   .03 -.52 .624 
 AED amount  -.05 -1.17 .240   -.04 -.78 .461 
 AED side effects  .02 .54 .602   .07 1.64 .095 
Illness Perceptions .21     .13    
              IPQ-R timeline, acute/chronic  -.08 -2.01 .029   -.08 -1.78 .079 
              IPQ-R-consequences  .10 2.06 .036   .16 2.80 .009 
              IPQ-R-personal control  -.02 -.39 .653   -.01 -.08 .942 
              IPQ-R treatment control  -.01 -.23 .833   -.15 -2.93 .006 
              IPQ-R illness coherence  -.05 -1.31 .189   -.01 -.32 .770 
              IPQ-R timeline cyclical  .05 1.26 .212   -.04 -.77 .472 
              IPQ-R emotional representations  .13 2.76 .018   .02 .34 .728 
Metacognitive beliefs   .26     .13    
 MCQ 30; Positive beliefs   .01 .26 .781   -.08 -1.76 .085 
 MCQ 30; Negative beliefs  .54 11.62 .001   .23 4.07 .001 
 MCQ 30; Cognitive confidence  .03 .76 .432   .16 3.60 .001 
 MCQ 30; Need to control thoughts  .06 -.06 .951   .22 4.07 .001 
 MCQ 30; Cognitive self-consciousness  .06 1.49 .155   -.12 -2.50 .019 
Model summary          
R
2
 .73    R
2
 .58    
Adj R
2
 .51 
 
p= .000   Adj R
2
 .31 
 
p=.000   
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Table 3:  Additional variance explained by each variable group after reversing 
metacognitive beliefs and illness perceptions in  hierarchical regression  
                                                        Anxiety            Depression 
 R
2
  
change 
 R
2
 
change 
 
Demographics .04  .05  
Epilepsy characteristics .01  .03  
Metacognitive beliefs .43  .22  
Illness perceptions   .04  .04  
 
3.3 Mediation of relationship between metacognitive beliefs, anxiety and depression  
Results of the mediation analyses which examined the theoretically predicted role of 
the CAS in mediating the relationship between metacognitive beliefs and anxiety and 
depression symptoms are shown in Figures 1-4. When controlling for the influence of illness 
perceptions, the untested metacognitive beliefs and demographic and epilepsy characteristics 
the CAS had no mediational relationship between positive metacognitive beliefs and anxiety 
symptoms (Figure 1) (ab = -.01, BCa 95%, CI = -.03-.02) or depression symptoms (Figure 3) 
(ab = -.01, BCa 95%, CI = -.04-.02).  
          When the relationship between negative metacognitive beliefs about the 
uncontrollability and danger of worry and anxiety symptoms was examined the CAS partially 
mediated the relationship (Figure 2) as there was a significant indirect effect mediated by the 
CAS (ab = .09, BCa 95%, CI = .06-.13) and the direct effect remained significant. The 
relationship between negative metacognitive beliefs about the uncontrollability and danger of 
worry and depression was fully mediated by CAS (Figure 4). There was a significant indirect 
effect mediated by the CAS (ab = .13, BCa 95%, CI = .08-.18), but no direct effect. 
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                         b= -.07, ns                                                                b = .09*                                            
 
                                                                       c’(c) 
                                                         
                                                        b = .02, ns (b= .01, ns) 
Fig 1. Mediation of positive metacognitive beliefs (PMCB) on anxiety symptoms (HADS-A), via CAS 
components (CAS-1).  
 
 
                
                      b = 1.04 *                                                                     b =.09* 
c’ (c) 
 
b = .37*(b = .09*) 
Fig 2. Mediation of negative metacognitive beliefs about the uncontrollability and danger of worry (NMCB) on anxiety 
symptoms (HADS-A), via CAS components (CAS-1).  
 
 
 
                          b = -.07, ns                                                                b = .12 * 
 
                                                                        c’ (c) 
 
b = -.07, ns (b = -.01, ns) 
Fig 3. Mediation of positive metacognitive beliefs (PMCB) on depression symptoms (HADS-D), via CAS components 
(CAS-1).  
PMCB HADS-A 
CAS-1 
NMCB HADS-A 
CAS-1 
PMCB HADS-D 
CAS-1 
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                         b=1.04*                                                                           b=12* 
c’ (c) 
    b = .08, ns (b = .13*) 
Fig 4. Mediation of negative metacognitive beliefs about the uncontrollability and danger of worry (NMCB) on depression 
symptoms (HADS-D), via CAS components (CAS-1).   
 
4. Discussion 
4. Discussion 
4. Discussion 
This study provides further support for the S-REF model’s applicability to anxiety and 
depression in PWE. Metacognitive beliefs explained greater variance in anxiety and 
depression in PWE compared to negative illness perceptions.  The results also supported 
some of the key theoretical predictions derived from the S-REF model about the association 
between metacognitive beliefs, CAS and emotional distress. 
           When controlling for a range of variables considered to contribute to anxiety and 
depression in PWE; demographics (age, gender, employment status, educational status, 
marital status), epilepsy characteristics (seizure frequency in the past 12 months, polytherapy 
vs monotherapy and AED side-effects) and illness perceptions, metacognitive beliefs added 
significantly to the variance in symptoms of anxiety, explaining an additional 26%, and 
symptoms of depression explaining an additional 13%. When demographics, epilepsy 
characteristics and metacognitive beliefs were controlled for, illness perceptions only 
explained an additional 4% of the variance in both anxiety and depression symptoms. 
NMCB HADS-D 
CAS-1 
Notes: All analyse  controlled for: age, gender, education, marital status employment, seizure frequency- last 12 
months, AED amount, AED side-effects, IPQ-R (all subscales), MCQ-30 (all subscales excluding the one directly 
tested in the mediational anlyses). N = 457 (5,000 bootstraps). *p < 0.001, ns = non–significant.           
 
61 
 
 
 
Furthermore when controlling for participant demographics and epilepsy characteristics, 
metacognitive beliefs accounted for more of the remaining variance than illness perceptions 
in both anxiety (43% vs. 21%) and depression (22% vs. 13%).  
In the anxiety regression model, ‘negative metacognitive beliefs about the 
uncontrollability and danger of worry’ made the largest single contribution. This is consistent 
with the predictions of the S-REF model and with previous studies in epilepsy [39], and other 
physical health populations including cancer [43] and Parkinson’s disease [44]. No other 
metacognitive beliefs made independent contributions to anxiety in the final model. There 
were three illness perceptions that made independent contributions. ‘Emotional 
representations’ and ‘consequences’ had a positive relationship with anxiety outcome scores, 
and ‘timeline (acute/chronic)’ had a negative relationship with anxiety outcome scores. This 
suggests individuals with negative perceptions about the emotional effects of their epilepsy 
and individuals who strongly perceive their epilepsy has negative consequences for them are 
likely to have greater anxiety. Whereas individuals who perceive that their epilepsy is chronic 
are likely to have less anxiety. From the covariates, gender and marital status made 
independent contribution, with being male, and not being in a relationship associated with 
lower anxiety scores.   
In the depression regression model, four metacognitive beliefs and two illness 
perceptions made independent contributions. Similarly to the anxiety model, ‘negative beliefs 
about the uncontrollability and danger of worry’ made the largest individual contribution, 
again supporting the theoretical predictions of the S-REF model and mirroring results 
exploring depression in previous epilepsy [39], and other physical health studies [43,44]. The 
metacognitive belief ‘need to control thoughts’ made the next largest contribution indicating 
that more conviction in the belief about the need to control thoughts was strongly associated 
with higher depression.  Lack of ‘cognitive confidence’ was also strongly associated with 
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depression. Potentially this relationship occurs as worry and rumination may be a 
compensatory strategy for perceived lack of cognitive confidence which accentuates the 
belief that worry and rumination are uncontrollable, which leads to emotional distress[31,39].  
The ‘consequences’ subscale on the IPQ-R was also significant suggesting those with a 
strong belief that their epilepsy has negative consequences are likely to have higher levels of 
depression. 
Two subscales had a significant negative relationship with depression outcome score. 
Firstly, the metacognitive subscale ‘cognitive self-consciousness’, implying those who tend 
to pay close attention to the way their mind works and monitor their thoughts have fewer 
depression symptoms. Secondly, the illness perception ‘treatment control’, inferring those 
with a strong belief in their ability and power in controlling their epilepsy are likely to have 
fewer depression symptoms. 
The mediational analyses found that when controlling for potentially confounding 
variables the CAS partially mediated the relationship between negative metacognitive beliefs 
about the uncontrollability and danger of worry and anxiety. This is consistent with the S-
REF model which postulates negative metacognitive beliefs about the uncontrollability and 
danger of worry (e.g., “my worrying is uncontrollable”) have a direct relationship with 
anxiety and additionally further increase distress through activating the CAS. Conversely, the 
CAS fully mediated the relationship between negative metacognitive beliefs about the 
uncontrollability and danger of worry and depression as there was no direct effect 
established. Cook et al [43] found a comparable relationship in cancer patients. They 
considered the absence of any direct effect between negative metacognitive beliefs about the 
uncontrollability and danger of worry and depression may be due to wording on the ‘negative 
metacognitive beliefs about the uncontrollability and danger of worry’ subscale on the MCQ-
30, which specifically focuses on beliefs regarding worry over different forms of 
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perseverative thinking such as rumination, which are more closely associated to depression 
[43].  
The prediction that the CAS would fully mediate the relationship between positive 
metacognitive beliefs (e.g., ‘worrying helps me to avoid problems in the future’) and anxiety 
and depression was not supported. S-REF theory would predict that, although positive 
metacognitive beliefs increase the likelihood that an individual will be guided towards the 
selecting the CAS, it is the negative metacognitive beliefs about the uncontrollability and 
danger of worry that are most influential in emotional distress as they intensify and maintain 
the processes of the CAS.  
Results imply that in clinical practice it may be beneficial to considering alternatives 
to CBT, which is currently recommended as a psychological intervention for PWE)[56]. CBT 
largely focuses its approach on modifying the content of illness perceptions, which from 
results here, are seemingly less influential in predicting anxiety and depression than an 
alternative mechanism, metacognitive beliefs.  Results suggest if an individual’s erroneous 
metacognitive beliefs are accounted for, then their illness perceptions have little influence in 
anxiety and depression in PWE. This implies the associated treatment of the S-REF model; 
metacognitive therapy (MCT), may have more suitability as a psychological intervention for 
anxiety and depression in PWE. MCT is a ‘process focused’ approach which centers on 
modifying metacognitive beliefs, altering an individual’s relationship with their thoughts , 
and exploring unhelpful processing styles that lead to distress. Results here show an 
individual’s ‘negative metacognitive beliefs about the uncontrollability and danger of worry’ 
are the key influence in anxiety and depression in PWE. Exploring and attempting to modify 
these beliefs in therapy through MCT could be an effective approach to reduce individuals 
using components of the CAS which was shown to further increase distress in both anxiety 
and depression in this sample.   
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 Results showed a greater explanative ability in the process and style of how people 
respond to their thoughts rather than the content of their thoughts in influencing anxiety and 
depression in PWE. This study has thus provided support for ‘third wave’ therapeutic 
approaches which encourage individuals to respond to inner thoughts in a flexible way, and 
has built on previous research using techniques such as mindfulness and ACT as a therapeutic 
approach for PWE [34-36] 
There are several limitations to the study, the cross sectional design means causality 
cannot be inferred and it may be that maladaptive metacognitive beliefs are the consequence 
of emotional distress, rather than the cause.  To provide more convincing evidence of 
causation, conducting a prospective test of the S-REF model to explore the temporal 
precedence of metacognitive beliefs for anxiety and depression in PWE would be necessary. 
The temporal precedence of metacognitive beliefs has been established in many conditions 
such as generalised anxiety disorder [57], depression [58], obsessive compulsive disorder 
[59] and anxiety and depression symptoms in cancer patients [44].  
Although the mediation analyses controlled for several recognised covariates of 
anxiety and depression in PWE this was based on the assumption of no hidden confounders. 
As such the potential influence of some unmeasured common causes cannot be eliminated. 
Gandy, Sharpe and Perry’s [17] review identified self-efficacy, stress levels, and perceived 
social support as variables associated with emotional distress in PWE. More robust findings 
may be found in future studies through controlling for these variables. 
Furthermore, the study sample may be unrepresentative of the wider population of 
epilepsy. Our sample contained only 28% of individuals who were seizure free over the past 
12 months in comparison to 51% seen in the wider population with epilepsy [60]. This may 
be due to recruiting through epilepsy organisations, which can be overrepresented with 
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people with more severe epilepsy [61]. Also the percentage of our sample meeting borderline 
or ‘caseness’ levels of anxiety and depression on the HADS was much higher than found in 
previous large scale studies of  PWE [3,4]. In particular ‘caseness’ levels on the HADS-A in 
our sample was significantly higher (61.7%) than a previous large scale study (20.5%) [4]. 
Additionally, females were over represented in our sample by 24% and the average age of our 
sample was eight years younger in comparison to the wider epilepsy population [60]. Our 
samples mean age at diagnosis and mean duration of their epilepsy were though comparable 
to the wider epilepsy population [60].  
5. Conclusion 
This study demonstrated metacognitive beliefs and processes contribute to anxiety 
and depression in PWE more than illness perceptions, thereby providing further support for 
the applicability of the S-REF model.  This suggests that the associated treatment of the S-
REF model; metacognitive therapy (MCT) may have potential in treating anxiety and 
depression in PWE. To further explore the potential of MCT for anxiety and depression in 
PWE, preliminary tests of MCT are required using case series and open trial designs.  If 
evidence of potential efficacy is obtained, then randomized controlled trials should follow. 
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Reference to a chapter in an edited book: [3] Mettam GR, Adams LB. How to prepare an 
electronic version of your article. In: Jones BS, Smith RZ, editors. Introduction to the 
electronic age, New York: E-Publishing Inc; 2009, p. 281–304.  
Reference to a website: [4] Cancer Research UK. Cancer statistics reports for the UK, 
http://www.cancerresearchuk.org/ aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 
13.03.03].  
Citation of a reference as 'in press' implies that the item has been accepted for publication. 
Note shortened form for last page number. e.g., 51–9. For further details you are referred to 
'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 
1997;277:927–34) (see also Samples of Formatted References).  
Journal abbreviations. Journal names should be abbreviated according to the List of Title 
Word Abbreviations. 
Acknowledgements- Collate acknowledgements in a separate section at the end of the article 
before the references  
For full author guidelines see:  
https://www.elsevier.com/wps/find/journaldescription.cws_home/622822?generatepdf=true 
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Appendix 2 
Sample e-mail to authors requesting individual patient data 
Dear Dr xxxxx, 
My name is James Reilly, I am a final year Trainee Clinical Psychologist working with Dr 
Peter Fisher at the University of Liverpool. 
We are currently in the process of conducting a clinical significance review of psychological 
interventions for depression and anxiety in people with epilepsy. In order to review the 
clinical significance, we intend to apply standardized Jacobson methodology to current 
psychological outcome trials for depression and anxiety in epilepsy. We are currently in the 
process of gathering raw data in order to conduct this review, and we would be grateful if we 
could include the data from your study: 
[insert study reference] 
As your work provides a very valuable contribution into this field, it would be extremely 
important to include your study in this review. Moreover, it would be a significant limitation 
to the review if your work was absent. Therefore, I would be grateful if you would be willing 
to send me the following: 
· Pre and post scores on the [insert primary measure stated in study] for each participant by 
treatment condition for all participants 
· Amount of sessions attended for each participant 
· Age of each participant 
The data can be sent as an SPSS file, excel file or a print out, whatever form would be most 
convenient for you. Above is a list for all the desired data; however, if you cannot provide all 
of the above, anything that you do provide would be very much appreciated. I understand that 
this is asking a lot, and would therefore be grateful if you could let me know whether or not 
this is something that you would be willing to help with. 
Thank you in advance for your help. If you have any queries of questions about the current 
research, please do not hesitate to contact me. I look forward to hearing from you. 
Yours sincerely, 
James Reilly 
Trainee Clinical Psychologist 
University of Liverpool 
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Appendix 3 
Data extraction form 
 Data Page Paragraph 
First Author:    
Year of Study:    
Country:    
    
Study Design:    
    
Sample Size:    
Mean Age 
(S.D): 
   
Female %:    
    
Intervention 
Type: 
(Psychological 
methods vs 
…) 
   
Intervention 
Delivery: 
(group/ 
individual/ 
face-to-face, 
facilitators: 
   
Intervention 
Duration: 
   
    
Inclusion 
Criteria: 
Epilepsy dx 
type: 
   
Emotional 
distress level: 
   
Age required:    
Other:    
    
Measures 
used: 
   
When 
measures 
used: 
   
    
Attrition rate 
%: 
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Mood 
outcomes, 
group x time 
interaction:   
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Appendix 4 
PEDro-P Scale  
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Appendix 5 
PEDro-P Scale administration guidelines 
The PEDro-P scale consists of 11 criteria. The first item relates to the external validity 
(specifically the participant selection criteria). The remaining 10 items (criteria 2 - 11) assess 
the internal validity of each trial and whether the trial contains sufficient statistical 
information to make it interpretable. Thus, the internal validity of each trial is ranked based 
on a total score out of 10 (i.e., excluding criterion 1). 
All criteria points are only awarded when a criterion is clearly satisfied. If on a literal reading 
of the trial report it is possible that a criterion was not satisfied, a point should not be awarded 
for that criterion. 
Criterion 1- Eligibility criteria were specified: This criterion is satisfied if the report 
describes the source of subjects and a list of criteria used to determine who was eligible to 
participate in the study. 
Criterion 2- Subjects were randomly allocated to groups (in a crossover study, subjects 
were randomly allocated an order in which treatments were received): A study is 
considered to have used random allocation if the report states that allocation was random. 
The precise method of randomisation need not be specified. Procedures such as coin-tossing 
and dice-rolling should be considered random. Quasi-randomisation allocation procedures 
such as allocation by hospital record number or birth date, or alternation, do not satisfy this 
criterion. 
Criterion 3- Allocation was concealed: Concealed allocation means that the person who 
determined if a subject was eligible for inclusion in the trial was unaware, when this decision 
was made, of which group the subject would be allocated to. A point is awarded for this 
criteria, even if it is not stated that allocation was concealed, when the report states that 
allocation was by sealed opaque envelopes or that allocation involved contacting the holder 
of the allocation schedule who was “off-site”. 
Criterion 4- The groups were similar at baseline regarding the most important 
prognostic indicators: At a minimum, in studies of therapeutic interventions, the report must 
describe at least one measure of the severity of the condition being treated and at least one 
(different) key outcome measure at baseline. The rater must be satisfied that the groups’ 
outcomes would not be expected to differ, on the basis of baseline differences in prognostic 
variables alone, by a clinically significant amount. 
This criterion is satisfied even if only baseline data of study completers are presented. 
Note: Criteria 4, 7-11 Key outcomes are those outcomes which provide the primary measure 
of the effectiveness (or lack of effectiveness) of the therapy. In most studies, more than one 
variable is used as an outcomemeasure. 
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Criterion 5- There was blinding of all subjects  
Criterion 6- There was blinding of all therapists who administered the therapy  
Criterion 7- There was blinding of all assessors who measured at least one key outcome. 
Note: Criteria 5-7: Blinding means the person in question (subject, therapist or assessor) did 
not know which group the subject had been allocated to. In addition, subjects and therapists 
are only considered to be “blind” if it could be expected that they would have been unable to 
distinguish between the treatments applied to different groups. In trials in which key 
outcomes are self-reported (eg, visual analogue scale, pain diary), the assessor is considered 
to be blind if the subject was blind. 
Criterion 8- Measures of at least one key outcome were obtained from more than 85% 
of the subjects initially allocated to groups: This criterion is only satisfied if the report 
explicitly states both the number of subjects initially allocated to groups and the number of 
subjects from whom key outcome measures were obtained. In trials in which outcomes are 
measured at several points in time, a key outcome must have been measured in more than 
85% of subjects at one of those points in time. 
Criterion 9- All subjects for whom outcome measures were available received the 
treatment or control condition as allocated or, where this was not the case, data for at 
least one key outcome was analysed by “intention to treat” : An intention to treat analysis 
means that, where subjects did not receive treatment (or the control condition) as allocated, 
and where measures of outcomes were available, the analysis was performed as if subjects 
received the treatment (or control condition) they were allocated to. This criterion is satisfied, 
even if there is no mention of analysis by intention to treat, if the report explicitly states that 
all subjects received treatment or control conditions as allocated. 
Criterion 10- The results of between-group statistical comparisons are reported for at 
least one key outcome: A between-group statistical comparison involves statistical 
comparison of one group with another .Depending on the design of the study, this may 
involve comparison of two or more treatments, or comparison of treatment with a control 
condition. The analysis may be a simple comparison of outcomes measured after the 
treatment was administered, or a comparison of the change in one group with the change in 
another (when a factorial analysis of variance has been used to analyse the data, the latter is 
often reported as a group × time interaction). The comparison may be in the form hypothesis 
testing (which provides a “p” value, describing the probability that the groups differed only 
by chance) or in the form of an estimate (for example, the mean or median difference, or a 
difference in proportions, or number needed to treat, or a relative risk or hazard ratio) and its 
confidence interval. 
Criterion 11- The study provides both point measures and measures of variability for at 
least one key outcome: A point measure is a measure of the size of the treatment effect. The 
treatment effect may be described as a difference in group outcomes, or as the outcome in 
(each of) all groups. Measures of variability include standard deviations, standard errors, 
confidence intervals, interquartile ranges (or other quantile ranges), and ranges. Point 
81 
 
 
 
measures and/or measures of variability may be provided graphically (for example, SDs may 
be given as error bars in a Figure) as long as it is clear what is being graphed (for example, as 
long as it is clear whether error bars represent SDs or SEs). Where outcomes are categorical, 
this criterion is considered to have been met if the number of subjects in each category is 
given for each group.   
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Appendix 6 
Ethical approval letter 
 
 
Dr Mantalena Sotiriadou Research Ethics and Integrity Officer                      
University of Liverpool  
Correspondence to; 
 Research Support Office  
University of Liverpool  
Waterhouse Building  
 2nd Floor, Block D  
3 Brownlow Street  
Liverpool 
 L69 3GL  
  
Email: ethics@liverpool.ac.uk  
Telephone: 0151 795 8355 
24 May, 2016  
 Dear Dr Fisher and Mr Reilly,  
Re: Ethical Approval 
  
I am pleased to inform you that your study has been approved. Details and conditions of the 
approval can be found below:    
Ethics reference number: RETH001034 
Committee name: Research Ethics Sub-committee for Physical Interventions  
Review type: Full committee review  
Supervisor: Dr Peter Fisher 
Student Investigator: Mr James Reilly 
Department: Psychological Sciences 
Title: An investigation into the relative contribution of cognitive and metacognitive beliefs in 
anxiety and depression in people with epilepsy.  
First reviewer: Professor Caroline Rowland  
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Date of approval: 24/05/16 
Approximate end date: 30/06/17    
 
The application was APPROVED subject to the following conditions:                                                                   
 
Conditions                                                                                                             
 All serious adverse events must be reported to the Subcommittee within 24 hours 
of their occurrence, via the Research Integrity and Governance Officer 
(ethics@liverpool.ac.uk).         
        
 This approval applies for the duration of the research.  If it is proposed to extend 
the duration of the study as specified in the application form, the Subcommittee 
should be notified, via the Research Integrity and Governance Officer 
(ethics@liverpool.ac.uk).  
 
 If it is proposed to make an amendment to the research, you should notify the 
Committee by following the Notice of Amendment procedure. If the named PI / 
Supervisor leaves the employment of the University during the course of this 
approval, the approval will lapse. Therefore please contact the Research Integrity 
and Governance Officer at ethics@liverpool.ac.uk in order to notify them of a 
change in PI / Supervisor.  
  
Yours sincerely,  
  
Dr Mantalena Sotiriadou  
Research Ethics and Integrity Office 
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Appendix 7 
Sample advert (used online by ‘Epilepsy Scotland’) 
 
 
 
Study title: Understanding anxiety and depression in people with epilepsy 
Institution  
University of Liverpool 
About the study 
We want to get a better understanding of how anxiety and depression come about in people 
with epilepsy. This will help tell us which psychological treatments are best suited to 
reducing anxiety and depression in people with epilepsy.  
As a thank you for taking part you will be offered the chance to enter a prize draw to win one 
of ten £20 Amazon gift vouchers. 
When will this study be recruiting?  
Now until February 2017 
What will participants be asked to do?  
Complete 5 online questionnaires, this should take no longer than 45 minutes to complete, 
and complete the same questionnaires 3 months later. 
Who can take part?  
You can take part if you: 
- Have a diagnosis of epilepsy  
- Are aged 18 or over 
- Are taking anti-epileptic medication 
- Have a good understanding of written English. 
 
Who is conducting the research?  
The Clinical Psychology Department at the University of Liverpool 
Who has reviewed this study? 
The research and ethics committee at the University of Liverpool have reviewed the study 
and granted ethical approval for it to go ahead. 
Interested……..If you are interested in taking part please click on this link: 
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Appendix 8  
Participant information form 
 
 
 
 
PARTICIPANT INFORMATION SHEET  
 
Title of Study:  Research to better understand anxiety and depression in people with 
epilepsy  
 
We are inviting you to participate in a research study. Before you decide whether to 
participate, it is important you understand why we are doing the research and what it 
will involve. 
 
Please take time to read the following information carefully and feel free to ask us if you 
would like more information. Take time to decide if you wish to take part. We would 
like to say that you do not have to accept this invitation and should only agree to take 
part if you want to. 
 
1. What is the purpose of the study? 
 
The University of Liverpool is carrying out a research project, which aims to further our 
understanding about anxiety and depression in people with epilepsy.  Unfortunately anxiety 
and depression are common in epilepsy but relatively little is known about the psychological 
factors that contribute to this. This research aims to further our understanding about 
how depression and anxiety is maintained in people with epilepsy. In the future this may help 
to develop more effective psychological treatments. 
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2. Why have I been chosen to take part? 
 
We are inviting anyone with a diagnosis of epilepsy, taking anti-epileptic medication aged 18 
or over to complete a set of questionnaires that ask about, how they make sense of their 
epilepsy, their emotional reactions, and some basic details about the nature of their epilepsy.  
 
It is possible that some people will currently have symptoms of depression and anxiety, or 
have had these in the past, whereas others may never have experienced depression and 
anxiety.  It is important to include people with different experiences so we can build a more 
complete picture. The invitation to take part in the study does not mean that we think you are 
having problems with depression and anxiety or are finding it hard to cope.   
   
3. What will happen if I take part? 
 
If you take part, the researchers will ask you to do the following things: 
 To fill in some questionnaires online at two separate time points. The 
first time will be when you agree to take part and the second time will be 3 
months after this. We are asking you to repeat the questionnaires so we can 
see if there are any changes in the anxiety or depression that you may be 
experiencing. 
 Before you answer the questionnaires, you will see some statements 
about the research and your rights. Please read these and ‘tick’ these boxes if 
you agree with them. This will act as your consent to take part. After this the 
questionnaires will appear. These will take no longer than 45 minutes to 
complete all together. 
  Some of the questions ask you about your epilepsy directly, some ask 
about how you have been feeling and some ask about how you think about 
your epilepsy. At the start of the survey, you will be asked to fill in some 
personal information (e.g., age, employment status, marital status) we ask 
these questions to help us better understand the results. You can choose not 
to answer these questions if you wish. 
 If you wish to take break whilst doing the questionnaires you can as the 
questionnaire page will not ‘time out’. Also, if you do not want to finish the 
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survey in one sitting you can click the ‘save and continue’ button. This will 
allow you to return to where you left off the next time you click the survey 
link. However, if you want to use this option you must use the same 
computer and the same web browser and must have not cleared your browser 
cookies. 
 At the end of the questionnaires, we will ask you to provide an e-mail 
address, which we can contact you on to provide you with the webpage to 
complete the questionnaires 3 months later. Once we have your completed 
second questionnaires back this will be all you need to do for the study and 
your e-mail address will be destroyed. 
 To thank you for taking part we will also ask if you would like to be 
entered into a prize draw to win a £20 amazon voucher (10 available). 
 All of the information you supply will be kept confidential whilst the 
data is being collected. When data collection is completed, your data will be 
anonymised and following University Research Data Management policy 
will be retained for a minimum of 10 years.      
 
4.     What are the possible benefits of taking part? 
 
Knowledge gained may lead to a better understanding of psychological factors involved in 
anxiety and depression in epilepsy and help decide future treatment. 
 
5. Are there any risks in taking part? 
 
There are no known risks of taking part and the questionnaires you will be asked to complete 
have been given to lots of people with epilepsy before. However, some of the questions do 
involve you thinking about the impact your epilepsy has on your life. For some people, this 
might be upsetting.  
 
If answering the questionnaires does make you feel any discomfort, please contact the 
principal Investigator: Dr Peter Fisher (0151 794 4160, plfisher@liverpool.ac.uk). We also 
suggest that you talk to your GP if this situation arises. Detailed information about the 
challenges of living with epilepsy can be found on the websites of the British Epilepsy 
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Association (http://www.epilepsy.org.uk/old-info) and the National Society for Epilepsy 
(http://www.epilepsysociety.org.uk/AboutEpilepsy)”  
 
6.  Will my participation be kept confidential? 
 
Yes. All of the information you provide will be stored securely and kept confidential.  Your 
name and contact details will not appear on any of the data collected. When you complete the 
questionnaires online, the answers will be transferred automatically to a secure database to 
enable it to be analysed with data from other participants. Your e-mail addresses will only be 
used to contact you 3 months after the first set of questionnaires to ask you to take part in the 
second part of the study and if you would like to be entered into the prize draw.  E-mail 
addresses will be destroyed after this. 
 
7. What if I do not want to take part anymore after I agree to take part? 
 
If you decide to take part and then want to change your mind, you can do this at any point.  
To do this you will just have to click the ‘withdraw from study’ option at the bottom of your 
screen and we would not collect any more information from you. Results up to the period of 
withdrawal may be used, if you are happy for this to be done. You may contact the primary 
supervisor to request that they are destroyed and no further use is made of them. 
  
8. What if I am unhappy or if there is a problem? 
 
If you are unhappy with the study please feel free to let us know by contacting the primary 
supervisor of the project Dr Peter Fisher (plfisher@liverpool.ac.uk, Tel: 0151 794 4160). If 
you have a complaint, which you feel you cannot come to us with then please contact the 
Research Governance Officer at ethics@liv.ac.uk . When contacting them, please provide 
details of the name or description of the study, the researcher(s) involved, and the details of 
the complaint you wish to make. 
 
9. What will happen to the results of the project? 
 
We shall report the results in scientific journals and we will not identify you in any report. A 
summary of the results will also be sent to the epilepsy groups who helped us recruit who 
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may display these for public viewing on their websites or in their newsletters. If you would 
like a copy of the final paper, you can contact the primary researcher and they will provide 
you with this. 
 
10.  Are there any reasons that would mean I could not take part? 
 
If you have difficulty understanding written English or if you cannot understand some of the 
words in the questionnaires, we would kindly ask you not to take part.  
 
      12.  Who can I contact if I have further questions? 
 
Should you need further information about the project you can contact the student 
investigator, James Reilly, reillyj@liverpool.ac.uk  or the primary supervisor of the study Dr 
Peter Fisher- 0151 794 4160, plfisher@liverpool.ac.uk. 
 
 
 
Thank you for reading this. 
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Appendix 9 
Participant consent form  
 
PARTICIPANT CONSENT FORM  
 
 
Study title: Research to better understand anxiety and depression in people with 
epilepsy  
  
In order to proceed with the study please read the following statements:              
 
 I confirm that I have read and understand the information sheet dated for the above 
study. I have been given the opportunity to consider the information, ask questions 
and have these answered satisfactorily.                                  
             Yes       No 
            ☐           ☐  
 
 I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason and without my rights being affected. In addition, 
should I not wish to answer any particular question or questions, I am free to decline.                                             
Yes       No 
           ☐           ☐  
 
 I give permission for members of the research team to have access to my responses. I 
understand I will not be identified or identifiable in the report or any publications that 
result from the research. I understand that my data will be anonymised upon 
completion of the research and following University Research Data Management 
policy will be retained for a minimum of 10 years.                                                                                                                                                 
Yes       No 
           ☐           ☐  
 
 
 I agree to take part in the study.   
           Yes       No 
          ☐           ☐  
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Appendix 10 
Participant debrief form 
 
 
 
 
DEBRIEF INFORMATION SHEET  
 
Title of Study:  Research to better understand anxiety and depression in people with 
epilepsy  
 
Thank you for completing the questionnaires. 
 
 If answering the questionnaires made you feel any discomfort, we would 
advise accessing information about the challenges of living with epilepsy. This 
can be found on several epilepsy websites such as the British Epilepsy 
Association (http://www.epilepsy.org.uk/) and the National Society for Epilepsy 
(http://www.epilepsysociety.org.uk/AboutEpilepsy).  We also suggest that you 
talk to your GP if this situation arises.  Further avenues of support can be 
advised by contacting the primary supervisor of the project Dr Peter Fisher 
(plfisher@liverpool.ac.uk, Tel: 0151 794 4160).  
 
 If you are unhappy with the study please feel free to let us know by contacting 
the primary supervisor of the project Dr Peter Fisher (plfisher@liverpool.ac.uk, 
Tel: 0151 794 4160). If you have a complaint, which you feel you cannot come 
to us with then please contact the Research Governance Officer at 
ethics@liv.ac.uk . When contacting them, please provide details of the name or 
description of the study, the researcher(s) involved, and the details of the 
complaint you wish to make. 
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Appendix 11 
Demographics and Medical History Questionnaire 
 
 
 
To help us understand more about you and your epilepsy, please answer the following 
questions:  
1. What is your date of birth? 
Day: 
Month: 
Year: 
 
2. What is your gender 
 Female 
 Male 
 
3. In which country do you live in? 
 Wales 
 Scotland 
 England 
 Northern Ireland 
 Republic of Ireland 
 
4. What is your ethnic group? 
 White 
 Black or African American 
 Asian 
 Mixed ethnic origin 
 Other 
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5. What is your marital status? 
 Single 
 Married 
 Divorced 
 Widowed 
 
6. At what stage did you finish education? 
 Before exam stage 
 'O' Levels, GCSE, Level 1 or 2 NVQ 
 'AS' or 'A' levels, Level 3 NVQ 
 University degree, graduate certificate, Diploma 
 Post graduate university degree (e.g. PGCE, MSc, MA, PHD) 
 
7.  What is your present work situation? 
 Employed, full-time 
 Employed, part-time 
 Self-employed 
 Unemployed 
 Retired  
 Student 
 Housewife/Househusband 
 
8. Do you regularly drive a motor vehicle? 
 Yes 
 No 
 
9. How old were you when you were first diagnosed with epilepsy (this may be different 
to when you had your first epileptic seizure)? 
 
10. Approximately, how many epileptic seizures (any type) have you had in the past 12 
months? 
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11. What is the cause of your seizures? 
 Head trauma/injury 
 Stroke 
 Brain tumor 
 Unknown 
 Other, please specify: ____________________ 
 
12. What type of seizures do you have? (You may select multiple answers). I have 
seizures where ... 
 I am aware of what is happening (such as simple focal seizures) 
 I am confused or only partly aware (such as complex focal seizures) 
 I briefly lose consciousness (such as absences, tonic and atonic seizures) 
 I lose consciousness and jerk or convulse (such as tonic-clonic seizures) 
 
13. How many different anti-epileptic medications are you being prescribed (please 
include any emergency rescue medication you may be prescribed)?  
 None 
 One medication 
 Two or more medications 
 
      14. Do you have any side-effects from taking your medication? 
 Yes 
 No 
 
     15. Who would you say is the main doctor for your epilepsy? 
 G.P 
 A hospital specialist (e.g., Neurologist) 
 G.P and hospital specialist are equally involved 
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Appendix 12 
The Hospital Anxiety and Depression Scale (HADS) 
 
Please read each item and place a firm tick in the box opposite the reply which comes 
closest to how you have been feeling in the past week. 
Don’t take too long over your replies: your immediate reaction to each item will probably be 
more accurate than a long thought-out response. 
 
Tick only one box in each section 
I feel tense or ‘wound up’:    I feel as if I am slowed down:   
 Most of the time 
............................... 
    Nearly all the time 
......................... 
  
 A lot of the time 
............................... 
    Very often 
...................................... 
  
 Time to time, Occasionally 
.............. 
    Sometimes 
..................................... 
  
 Not at all 
.......................................... 
    Not at all 
........................................ 
  
 
 
I still enjoy the things I used to 
enjoy: 
   I get a sort of frightened feeling 
like ‘butterflies’ in the stomach: 
  
 Definitely as much 
.......................... 
    Not at all 
........................................ 
  
 Not quite so much 
........................... 
    Occasionally 
.................................. 
  
 Only a little 
..................................... 
    Quite often 
..................................... 
  
 Hardly at all 
.................................... 
    Very often 
...................................... 
  
 
I get a sort of frightened feeling as 
if something awful is about to 
happen: 
    
I have lost interest in my 
appearance: 
  
 Very definitely and quite badly 
....... 
    Definitely 
.......................………… 
  
 Yes, but not too badly 
...................... 
    I don’t take so much care as I 
should 
  
 A little, but it doesn’t worry me 
...... 
    I may not take quite as much care 
.. 
  
 Not at all 
.......................................... 
    I take just as much care as ever 
...... 
  
 
I can laugh and see the funny side 
of things: 
   I feel restless as if I have to be on 
the move: 
  
 As much as I always could 
.............. 
    Very much indeed 
......................... 
  
 Not quite so much now 
.................... 
    Quite a lot ... 
.................................. 
  
 Definitely not so much now 
............. 
    Not very much 
............................... 
  
2 
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 Not at all 
........................................... 
    Not at all 
........................................ 
  
 
Worrying thoughts go through 
my mind: 
   I look forward with enjoyment to 
things: 
  
 A great deal of the time 
................... 
    As much as ever I did 
.................... 
  
 A lot of the time 
.............................. 
    Rather less than I used to 
............... 
  
 From time to time but not too 
often . 
    Definitely less than I used to 
.......... 
  
 Only occasionally 
............................ 
    Hardly at all 
.................................... 
  
 
I feel cheerful:    I get sudden feelings of panic:   
 Not at all 
.......................................... 
    Very often indeed 
.......................... 
  
 Not often 
......................................... 
    Quite often ... 
................................. 
  
 Sometimes 
....................................... 
    Not very often 
................................ 
  
 Most of the time 
.............................. 
    Not at all 
........................................ 
  
 
 
I can sit at ease and feel relaxed: 
   I can enjoy a good book or radio 
or TV programme: 
  
 Definitely 
........................................ 
    Often 
.............................................. 
  
 Usually 
............................................ 
    Sometimes 
..................................... 
  
 Not often 
......................................... 
    Not often 
...................................…. 
  
 Not at all 
......................................... 
    Very seldom 
................................... 
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Appendix 13 
Metacognitions Questionnaire 30 (MCQ-30) 
 
This questionnaire is concerned with beliefs people have about their thinking. 
Listed below are a number of beliefs that people have expressed.  Please read each item 
and say how much you generally agree with it by circling the appropriate number. 
Please respond to all items, there are no right or wrong answers. 
 
  Do not 
agree 
Agree 
slightly 
Agree 
moderately 
Agree 
very much 
1. Worrying helps me to 
avoid problems in the 
future 
1 2 3 4 
2. My worrying is dangerous 
for me 
1 2 3 4 
3. I think a lot about my 
thoughts 
1 2 3 4 
4. I could make myself sick 
with worrying 
1 2 3 4 
5. I am aware of the way my 
mind works when I am 
thinking through a problem 
1 2 3 4 
6. If I did not control a 
worrying thought, and then 
it happened, it would be 
my fault 
1 2 3 4 
7. I need to worry in order to 
remain organised 
1 2 3 4 
8. I have little confidence in 
my memory for words and 
names 
1 2 3 4 
9. My worrying thoughts 
persist, no matter how I try 
and stop them 
1 2 3 4 
10. Worrying helps me to get 
things sorted out in my 
mind 
1 2 3 4 
11. I cannot ignore my 1 2 3 4 
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worrying thoughts 
12. I monitor my thoughts 1 2 3 4 
13. I should be in control of my 
thoughts all of the time 
1 2 3 4 
 
14. My memory can misled 
me at times 
1 2 3 4 
15. My worrying could make 
me go mad 
1 2 3 4 
16. I am constantly aware of 
my thinking 
1 2 3 4 
17. I have a poor memory 1 2 3 4 
18. I pay close attention to 
the way my mind works 
1 2 3 4 
19. Worrying helps me cope 1 2 3 4 
20. Not being able to control 
my thoughts is a sign of 
weakness 
1 2 3 4 
21. When I start worrying, I 
cannot stop 
1 2 3 4 
22. I will be punished for not 
controlling certain 
thoughts 
1 2 3 4 
23. Worrying helps me to 
solve problems  
1 2 3 4 
24. I have little confidence in 
my memory for places 
1 2 3 4 
25. It is bad to think certain 
thoughts 
1 2 3 4 
26. I do not trust my memory 1 2 3 4 
27. If I could not control my 
thoughts, I would not be 
able to function 
1 2 3 4 
28. I need to worry, in order 
to work well 
1 2 3 4 
29. I have little confidence in 
my memory for actions 
1 2 3 4 
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30. I constantly examine my 
thoughts 
1 2 3 4 
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Appendix 14 
Illness Perceptions Questionnaire- Revised (IPQ-R) 
 
YOUR VIEWS ABOUT YOUR ILLNESS Listed below are a number of symptoms that you 
may or may not have experienced since your illness.  Please indicate by circling Yes or No, 
whether you have experienced any of these symptoms since your illness, and whether you 
believe that these symptoms are related to your illness.  
  
 I have experienced this symptom since my illness         This symptom is related to my illness  
    
Pain                                              Yes  No ________________ Yes  No  
Sore Throat                                   Yes  No ________________ Yes  No  
Nausea                                          Yes  No ________________ Yes  No  
Breathlessness                              Yes  No ________________ Yes  No  
Weight Loss                                   Yes  No ________________ Yes  No  
Fatigue                                           Yes  No ________________ Yes  No  
Stiff Joints                                      Yes  No ________________ Yes  No  
Sore Eyes                                      Yes  No ________________ Yes  No  
Wheeziness                                   Yes  No ________________ Yes  No  
Headaches                                    Yes  No ________________ Yes  No  
Upset Stomach                              Yes  No ________________ Yes  No  
Sleep Difficulties                            Yes  No ________________ Yes  No  
Dizziness                                       Yes  No ________________ Yes  No 
Loss of Strength                            Yes  No ________________ Yes  No 
 
 
We are interested in your own personal views of how you see your epilepsy. Please indicate 
how much you agree or disagree with the following statements about your epilepsy by 
selecting the appropriate box. 
 
1. My epilepsy will last a short time 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
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 Agree 
 Strongly agree 
 
2. My epilepsy is likely to be permanent rather than temporary 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
3. My epilepsy will last a long time 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
4. My epilepsy will pass quickly 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
5. I expect to have epilepsy for the rest of my life 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
6. My epilepsy is a serious condition 
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 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
7. My epilepsy has major consequences on my life 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
8. My epilepsy does not have much effect on my life 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
9. My epilepsy strongly effects the way others see me 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
10. My epilepsy has serious financial consequences 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
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 Strongly agree 
 
11. My epilepsy causes difficulties for those who are close to me 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
12. There is a lot I can do to control my symptoms 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
13. What I do can determine whether my epilepsy gets better or worse 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
14. The course of my epilepsy depends on me 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
15. Nothing I do will affect my epilepsy 
 Strongly disagree 
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 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
16. I have the power to influence my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
17. My actions will have no affect on the outcome of my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
18. My epilepsy will improve in time 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
19. There is very little that can be done to improve my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
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20. My treatment will be effective in curing my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
21. The negative effects of my epilepsy can be prevented by my treatment 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
22. My treatment can control my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
23. There is nothing that can help my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
24. The symptoms of my epilepsy are puzzling to me 
 Strongly disagree 
 Disagree 
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 Neither agree or disagree 
 Agree 
 Strongly agree 
 
25. My epilepsy is a mystery to me  
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
26. I don't understand my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
27. My epilepsy doesn't make any sense to me 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
28. I have a clear picture of understanding my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
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29. The symptoms of my epilepsy change a great deal from day to day 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
30. My epilepsy comes and goes in cycles 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
31. My epilepsy is very unpredictable 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
32. I go through cycles in which my epilepsy gets better and worse 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
33 .I get depressed when I think about my epilepsy 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
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 Agree 
 Strongly agree 
 
34. When I think about my epilepsy I get upset  
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
35. My epilepsy makes me feel angry 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
36. My epilepsy does not worry me 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
 
37. Having epilepsy makes me feel anxious 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
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38. My epilepsy makes me feel afraid 
 Strongly disagree 
 Disagree 
 Neither agree or disagree 
 Agree 
 Strongly agree 
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Appendix 15 
 
The Cognitive Attentional Syndrome Scale (CAS-1) 
 
 
1. How much time in the last week have you found yourself dwelling on or 
worrying about problems (e.g. health, family, finances)? (Circle a number 
below) 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None 
of the 
time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
2. How much time in the last week have you found yourself analysing your 
feelings/symptoms or questioning why did this happen to me? (Circle a 
number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None 
of the 
time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
3. How much time in the last week have you been focusing attention on the 
things you find  threatening (e.g. symptoms, thoughts, bodily checking)?  
(Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None 
of the 
time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
4. How much time in the last week have you avoided activity or certain 
situations?  (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None 
of the 
time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
5. How much time in the last week have you tried not to think certain 
thoughts? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None 
of the 
time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
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6. How much time in the last week have you used alcohol to cope with 
thoughts/feelings? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None 
of the 
time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
 
 
7. How much do you believe that worrying or dwelling on thoughts is 
uncontrollable? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
per 
cent 
certain 
     
Completely 
certain this 
is true 
 
8. How much do you believe that worrying or dwelling on thoughts is 
harmful? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
per 
cent 
certain 
     
Completely 
certain this 
is true 
 
9. How much do you believe that worrying is helpful? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
per 
cent 
certain 
 
     
Completely 
certain this 
is true 
 
10. How much do you believe that anticipating problems will keep you safe? 
(Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
per 
cent 
certain 
     
Completely 
certain this 
is true 
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Appendix 16 
Power Calculation 
A power analysis was undertaken to determine the sample size required to detect an effect of 
a given size with a given degree of confidence (Dancey & Reidy, 2002). The G*Power 
3.1.9.2 (Faul, Buchner, Erdfelder & Lang, 2009) programme calculated a minimum of 127 
participants would provide 80% power to identify an effect size of 0.15 with models 
containing up to 20 predictors at the p<0.05 significance.  
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